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ABSTRACT 
Primate lentiviruses encode four “accessory proteins” including Vif, Vpu, Nef, and 
Vpr/ Vpx. Vif and Vpu counteract the antiviral effects of cellular restrictions to early and 
late steps in the viral replication cycle. The functions of Vpx/ Vpr are not well understood. 
This study presents evidence that the Vpx proteins of HIV-2/ SIVSM promote HIV-1 
infection by antagonizing an antiviral restriction in myeloid cells.  
Fusion of macrophages in which Vpx was essential for virus infection, with COS 
cells in which Vpx was dispensable for virus infection, generated heterokaryons that 
supported infection by wild-type SIV but not Vpx-deleted SIV. The restriction potently 
antagonized infection of macrophages by HIV-1, and expression of Vpx in macrophages 
in trans overcame the restriction to HIV-1 and SIV infection. Similarly, the cellular 
restriction is the obstacle to transduction of macrophages by MLV. Neutralization of the 
restriction by Vpx rendered macrophages permissive to MLV infection. Vpx was 
ubiquitylated and both ubiquitylation and the proteasome regulated the activity of Vpx. 
The ability of Vpx to counteract the restriction to HIV-1 and SIV infection was 
dependent upon the HIV-1 Vpr interacting protein, damaged DNA binding protein 1 
(DDB1), and DDB1 partially substituted for Vpx when fused to Vpr. 
This study further demonstrates that this restriction prevents transduction of 
quiescent monocytes by HIV-1. Although terminally differentiated macrophages are 
 vi
partially permissive to HIV-1, quiescent monocytes, which are macrophage precursors, 
are highly refractory to lentiviral infection. Monocyte-HeLa heterokaryons were resistant 
to HIV-1 infection, while heterokaryons formed between monocytes and HeLa cells 
expressing Vpx were permissive to HIV-1 infection, suggesting the resistance of 
quiescent monocytes to HIV-1 transduction is governed by a restriction factor. 
Encapsidation of Vpx within HIV-1 virions conferred the ability to infect quiescent 
monocytes. Introduction of Vpx into monocytes by pre-infection also rendered quiescent 
monocytes permissive to HIV-1 infection. Infection of monocytes by HIV-1 either with 
or without Vpx did not have an effect on temporal expression of CD71. In addition, Vpx 
increased permissivity of CD71– and CD71+ cells to HIV-1 infection with no apparent 
bias. These results confirm that Vpx directly renders undifferentiated monocytes 
permissive to HIV-1 transduction without inducing their differentiation. The introduction 
of Vpx did not significantly alter APOBEC3G complex distribution, suggesting a 
restriction other than APOBEC3G was responsible for the resistance of monocytes to 
HIV-1. 
Collectively our results indicate that macrophages and monocytes harbor a potent 
antiviral restriction that is counteracted by the Vpx protein. The relative ability of primate 
lentiviruses and gammaretroviruses to transduce non-dividing myeloid-cells is dependent 
upon their ability to neutralize this restriction.  
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CHAPTER I                                   
Background and Introduction 
1.1 General Introduction to Primate Lentiviruses 
Human immunodeficiency virus (HIV) is the virus that causes acquired 
immunodeficiency syndrome (AIDS), which leads to opportunistic infections or 
malignancies due to CD4+ T cell depletion and the progressive failure of the immune 
system. According to the World Health Organization, as of Dec 2007, there were 33 
million people living with HIV, while 2 million deaths were affiliated to AIDS in 2007 
alone (1). AIDS is now one of the leading causes of death and loss of life quality 
worldwide. Effectively fighting HIV/AIDS is one of the most urgent challenges in the 
world. 
HIV and the closely related Simian immunodeficiency virus (SIV) are lentiviruses 
that belong to the retrovirus family, the Retroviridae. They are RNA viruses that encode 
reverse transcriptase (RT), which catalyzes the synthesis of cDNA from viral genomic 
RNA. Viral DNA is ultimately integrated into the host genome and the integrated 
proviral DNA directs gene expression. Below is a primate lentivirus phylogenetic tree. 
HIV-1 group M, which is responsible for the majority of the global AIDS pandemic, as 
well as groups N and O evolved from the chimpanzee virus SIVCPZ (2, 3). HIV-2, which 
is slightly attenuated with regards to disease progression, evolved from SIVSM, which 
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naturally infects sooty mangabey (4, 5). SIVSM was used to generate the various rhesus 
macaque-adapted SIVMAC viruses that are often used for AIDS pathogenesis study. There 
is another cluster that includes SIVAGM evolved from African green monkeys (Figure 1-1) 
(6). 
Lentiviral Pathogenesis and Reservoirs 
In its natural hosts, SIV does not cause AIDS even with high viral loads. However, 
SIV infection of rhesus macaques, and HIV-1 infection of human cause progression to 
AIDS. HIV-1 primarily infects immune cells including CD4+ T lymphocytes, tissue 
macrophages, and dendritic cells. Infection of these cells accounts for the major aspects 
of HIV-1 pathogenesis in vivo. The depletion of CD4+ T cells is the main reason for the 
progression to AIDS in HIV-1 infected patients. Upon initial HIV-1 infection, there is 
active viral replication but viral replication is limited by a strong immune pressure and 
this leads to the partial recovery of peripheral CD4+ T cells. Infection then enters an 
asymptomatic phase characterized by low levels of viral load with no disease symptoms, 
which ultimately leads to loss of cell-mediated immunity due to a reduction in CD4+ T 
cell numbers. This is the onset of the AIDS stage in which the patient becomes 
progressively more susceptible to opportunistic infections that inevitably lead to death in 
the vast majority of untreated patients (7). This model was primarily based on the study 
of the peripheral CD4+ T cell counts. Recent studies showed that  during  acute  HIV 
 3
 
 
HIV Sequence Compendium 2001 
 
Figure 1-1. The phylogenetic tree of primate lentiviruses (6). Phylogenetic 
relationships of primate lentiviruses with major clusters shown: HIV-1/SIVCPZ, 
HIV-2/SIVMAC/SIVSM, and SIVAGM. 
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infection, the frequency of infection was especially high in memory CD4+ T cells in the 
gut, and depletion of these cells led to increased gut permeability with microbial 
translocation. Higher circulating LPS level drives systemic immune activation and leads 
to chronic HIV infection (8, 9). 
HIV-1 infection of macrophages, dendritic cells and other non-T cells may also 
play essential roles in several critical aspects of HIV disease. In addition to CD4+ T 
lymphocytes, monocyte-macrophage lineage and dendritic cells may form viral 
reservoirs in HIV-1 infection. HIV-1 in macrophages is assembled in intracellular 
vesicles and virions can be transmitted from macrophages to T cells across transient 
virological synapses (10–12). HIV-1virions that are assembled intracellularly within 
monocyte-derived macrophages persist and retain infectivity for extended intervals (13), 
confirming that macrophages serve as a HIV-1 reservoir and contribute to viral 
persistence. In addition, macrophages are able to cross the blood-brain barrier and spread 
viruses in the immuno-privileged central nervous system (CNS) ( 14 ). Although 
monocytes express the required HIV-1 receptors and coreceptors, they are not 
productively infected by HIV-1 in vitro (15, 16). HIV-1 infection of freshly isolated 
blood monocytes is blocked prior to the completion of reverse transcription and 
integration (16). Several studies indicate that peripheral monocytes may also serve as a 
viral reservoir in vivo. HIV-1 can be detected in blood monocytes. However, whether the 
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viruses are produced or are maintained latently in monocytes is unclear (17–20). Other 
evidence support monocytes as a HIV-1 reservoir by showing that there is continued 
evolution of HIV-1 sequences in peripheral monocytes following antiviral therapy (21). 
CD16+ monocytes, which constitute about 5% of monocyte population, are more 
susceptible to HIV-1 infection and possibly harbor the viruses long-term in vivo (22). 
Dendritic cells may also play a important role in the dissemination of HIV-1 following 
primary infection, as they can capture virions at the site of infection and provide HIV-1 
access to the CD4+ T cells, by being infected and transmitting newly produced viruses, 
or by harboring infectious viruses without being infected (23). Studies have suggested 
that DC-SIGN mediates the capture and internalization of infectious virions that are 
subsequently transmitted to T cells, via the immunological synapses formed between 
dendritic cells and T cells (24). 
HIV-1 genome organization and viral proteins 
Nine open-reading frames are found in the HIV-1 genome, encoding viral gene 
products that include structural proteins, enzymes for virus replication, and proteins that 
regulate viral gene expression. The gag and env genes encode the structural proteins and 
the pol open-reading frame encodes the enzymatic proteins. They are common to all 
retroviruses.  
The functions of HIV-1 gene products are reviewed in Fields virology (7). The 
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mature proteins of Matrix (MA, p17), Capsid (CA, p24), Nucleocapsid (NC, p7) and p6 
are cleaved from the Gag polyprotein by the virus-encoded protease during maturation. 
MA is responsible for membrane anchoring and interacts with envelope. MA also 
contains cytotoxic T-lymphocyte (CTL) epitopes. CA is an important structural protein 
that forms the conical core of the viral particle. NC binds and incorporates viral RNA 
into virions. P6 contains a late domain that promotes virus release, and Vpx/Vpr binding 
domains that mediate the incorporation of Vpx/ Vpr proteins into assembling virions. 
Several distinct enzymatic proteins are encoded by the pol open-reading frame, 
including protease (PR, p15), reverse transcriptase (RT, p66/ p51), and integrase (IN, 
p31). PR is responsible for Gag/ Pol cleavage and maturation. RT has RNA-dependant 
and DNA-dependant polymerase activity and synthesizes DNA from viral RNA, while 
the RNase H activity of RT removes the RNA template strand from the RNA/ DNA 
duplex. IN catalyzes viral DNA integration into the host genome. RT and PR are the 
most targeted enzymes in antiviral therapies. 
Env glycoprotein is cleaved by a cellular endopeptidase to yield gp120 surface (SU) 
and gp41 transmembrane (TM) proteins. Gp120 interacts with the CD4 receptor and 
chemokine coreceptors. Gp41 traverses the lipid bilayer and non-covalently binds to 
gp120, thus mediates the fusion of viral and cellular membranes. 
HIV-1 gene expression is regulated by Tat (transactivator of transcription) and Rev 
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(regulator of virion expression) at the transcriptional and posttranscriptional levels, 
respectively. Tat (p16/ p14) is an essential viral transcriptional activator that promotes 
efficient HIV-1 long terminal repeat (LTR) specific viral transcription. This requires 
interaction of Tat with transactivation response element (TAR) which is located in the R 
region of LTR5. Rev (p19) is an RNA transporter and stabilizer. Rev binds to Rev 
Response Element (RRE) and mediates the exportation of incompletely spliced mRNA 
that contains RRE to the cytoplasm, thus allows the production viral RNA genome and 
mRNA for viral proteins. The cellular Crm1 nuclear export factor is recruited to HIV-1 
transcripts by Rev and thereby facilitates their nuclear egress. 
The genomes of primate and non-primate lentiviruses also encode ‘accessory’ 
proteins from small open reading frames which are absent from the genomes of simple 
retroviruses. They are Vif (viral infectivity factor), Vpx (viral protein x)/ Vpr (viral 
protein r), Vpu (viral protein u), and Nef (negative factor). Accessory proteins were so 
named because they were dispensable for viral replication in some cell lines. However, 
recent studies have shown that they all play crucial roles in lentiviral replication and 
persistence (reviewed in (25)). Nef (p27) down regulates the major viral receptor CD4, 
the major histocompatibility complex (MHC) class I and class II molecules, as well as 
the T cell receptor TCR-CD3 (26–29). Two of the accessory proteins, Vif and Vpu, 
have been found to overcome restriction factors. Vif antagonizes the antiviral activity of 
 8
APOBEC3G (30). Vpu, which is not expressed in HIV-2 and SIVSM, antagonizes the 
activity of tetherin/ BST-2 (Bone marrow stromal cell antigen 2) to promote the release 
of virions from the cell surface (31). Vpu also mediates CD4 receptor degradation (32). 
Vpx and Vpr both play important but less well defined roles in viral replication. Vpr has 
been reported to induce G2 cell cycle arrest and to promote HIV-1 infection in 
macrophages (33–37). HIV-2/SIVSM encodes an additional accessory protein Vpx, 
which is derived from an ancestral recombination event (38). Vpx is essential for SIV 
replication in simian macrophages and for dissemination and pathogenesis of SIV in vivo 
(38–40). 
Lentiviral LTRs, which are composed of U3, R, and U5, contain important 
regulatory regions such as those for transcription initiation and polyadenylation. They 
are also the sequences the IN uses to insert viral cDNA into host genomes. 
Lentivirus life cycle 
In the replication cycle of HIV-1, the virions undergo binding, fusion and 
uncoating, reverse transcription, nuclear import, integration, transcription and translation, 
assembly and budding to produce new virions (Figure 1-2). Viral entry into the target 
cells is mediated through sequential interactions of HIV-1 Env with the primary receptor 
CD4, and coreceptors. CCR5 and CXCR4 appear to be the two major coreceptors for 
HIV-1 entry into cells. HIV-1 is categorized into R5  and  X4  tropic  based  on the 
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Rambaut A et al. Nat Rev Genet. 2004 Jan; 5(1):52-61. 
 
Figure 1-2. General aspects of the primate lentivirus replication cycle ( 41 ). 
Complete lentiviral life cycle is depicted as steps including virus binding, fusion and 
uncoating, reverse transcription, nuclear import, integration, transcription and translation, 
assembly and budding. 
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coreceptor usage during entry. Viruses that use the CCR5 receptor are termed R5 tropic, 
which mainly infect macrophages and dendritic cells. While those that use CXCR4 are 
termed X4 tropic, which mainly infect CD4+ T cells. However, coreceptor usage is not 
the only determinant for viral tropism and recent studies have shown that HIV-1 R5 
viruses vary extensively in macrophage tropism (42). In addition to CCR5 and CXCR4, 
alternative coreceptors are used by lentiviruses. More than 10 members of 
seven-transmembrane G protein-coupled receptors (GPCRs) have been shown to support 
lentiviral entry in vitro, including CCR2b, CCR3, CCR8, D6, CXCR5/BLR1, 
CXCR6/BONZO et al, although there is no clear evidence that they play a role in vivo 
(43–4 7). After fusion, the viral core is released into cytoplasm and subsequently 
disassembles to liberate the viral genome, during a process called uncoating. The viral 
genome associates with the viral proteins including RT, IN, MA, NC to form a 
pre-integration complex (PIC), in which the viral RT catalyzes the synthesis of a linear 
double-stranded cDNA from single- stranded viral RNA. After transportation of PIC into 
the nucleus, the viral cDNA is integrated into the host genome by HIV IN. This 
integrated provirus may remain latent in an unexpressed form, particularly in resting 
lymphocytes. Upon activation, host RNA polymerase is used to generate transcripts 
including new viral genomic RNA and spliced mRNA molecules, which are transported 
to the cytoplasm for protein synthesis. The production of viral RNA and proteins is 
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regulated by Rev and Tat proteins. The de novo synthesized viral proteins are assembled 
with HIV-1 genome and the newly assembled viruses bud from the plasma membrane of 
infected cells. During particle maturation, the virion associated PR cleaves the immature 
Gag and Gag–Pol precursors into functional viral proteins, leading to the production of 
infectious virions (7, 48). 
The reverse transcription of HIV-1 is characterized by two strand transfers and 
requires two enzymatic activities of RT, including DNA polymerase activity that can use 
RNA or DNA as a template and RNase H activity. The process is summarized in figure 
1-3 (49). The tRNA binds to the primer binding site (PBS) and initiates the synthesis of 
minus strand strong-stop DNA. RNase H activity of RT then removes the U5 and R 
region of the RNA. With the first strand transfer, the minus strand strong-stop DNA 
jumps to the 3’ end of RNA and serves as a primer for minus strand DNA synthesis. 
During the extension, RNase H removes the most of the viral RNA except for a region 
called polypurine-tract (PPT), which serves as a primer to initiate plus strand DNA 
synthesis. After completion of plus strand strong stop DNA, this small region of viral 
RNA and tRNA is removed. With the second strand transfer the newly synthesized plus 
strand strong stop DNA jumps to the opposite end and pairs up with minus strand DNA 
at PBS sequence. The extension of 3’ end on both strands is the last step for the synthesis 
of  linear  double-stranded  DNA  with LTR sequences on both ends. Viral cDNA is 
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Figure 1-3. Process of reverse transcription of the lentiviral genome (49). RNA 
strand is represented in black and DNA strand in red (A) Minus strand strong stop DNA 
synthesis is initiated by tRNA binding to the PBS. RNase H removes the U5 and R 
region of the RNA strand. (B) First strand transfers to the 3’ end of viral RNA and 
serves as primer for minus strand DNA extension. (C) Minus strand DNA extension, 
accompanied by RNase H digestion of all viral RNA except PPT. (D) PPT serves as a 
primer for plus strand strong stop DNA synthesis. (E) RNase H removes the tRNA and 
the PPT. (F) Minus and plus strands extend following second strand transfer and results 
in cDNA duplex with LTRs at both ends. 
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eventually integrated into the host genome, or forms circles containing one or two LTRs 
through recombination or direct ligation. Since 2-LTR circles are formed only after 
completion of reverse transcription, they can be used to determine the efficiency of 
reverse transcription post virus infection. 
1.2 Introduction to Restriction Factors 
Not all the cells support efficient viral infection. Cells that support efficient viral 
replication are called permissive cells. Cells that do not support efficient viral replication 
are called nonpermissive. Lentiviruses interact with various cellular factors throughout 
the viral life cycle. Nonpermissive cells either have evolved some mechanisms to restrict 
virus infection, or lack some positive factors that are essential for virus infection. Those 
host cellular factors whose expression restricts viral replication are named restriction 
factors. They constitute novel aspects of intrinsic immunity and act at different steps in 
the viral life cycle. Several restriction factors have been identified recently, including 
APOBEC3G, TRIM5α, and Tetherin (30, 31, 50, 51). Many lentiviruses, in turn, have 
evolved mechanisms to inactivate or overcome the blocks to infection. 
APOBEC3G (Apolipoprotein B mRNA-editing catalytic polypeptide 3G) 
Vif, a 23-kDa basic protein, is encoded by the majority of lentiviruses. As a 
cytoplasmic protein, Vif exists in a soluble cytosolic form or a membrane-associated 
form. The latter form of Vif is a peripheral membrane protein that is tightly associated 
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with the cytoplasmic side of cellular membranes (52). Vif is dispensable for viral 
replication in “permissive” cell lines such as SupT1, CEM-SS, C8166, HeLa and 293T 
cells. However, Vif is essential for viral replication in “nonpermissive” cells such as 
primary CD4+ T cells, monocyte-derived macrophages, and certain T-cell leukemia lines 
such as CEM (53–55). Vifminus virions produced in nonpermissive cells are poorly 
infectious, whereas Vif minus virions produced in permissive cells are able to infect both 
permissive and nonpermissive cell types (56, 57). 
In 2002, Sheehy and colleagues identified APOBEC3G through a cDNA 
subtraction screen for transcripts specifically expressed in nonpermissive cells (30). 
APOBEC3G belongs to the APOBEC superfamily, which consists of APOBEC1, 
APOBEC2, APOBEC3A to H, and the activation-induced deaminase (AID) gene (58, 
59). They share a conserved cytidine deaminase motif, which acts as DNA mutators that 
target the genome of viruses by catalyzing deamination of cytidine (C) to uridine (U) in 
minus strand reverse transcripts, resulting in guanidine (G) to adenosine (A) 
hypermutation in plus strand DNA (60-61). 61 In 62 the absence of Vif, APOBEC3G 
molecules are packaged into viral particles through interaction with viral RNA and Gag 
proteins (63, 64) and induce cytidine deamination in newly infected cells. Consequently, 
the infectivity of the virions produced from nonpermissive cells is dramatically impaired 
(Figure 1-4) (65). However, there is evidence that the enzymatic activity of APOBEC3G 
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Figure 1-4. Model of APOBEC3G mediated restriction (65). In the absence of Vif, 
APOBEC3G molecules are packaged into viral particles and induce G to A 
hypermutation in newly infected cells. Hypermutation of viral genomes leads to the 
degradation of nascent viral cDNA or mutations in viral genes, which hinders viral 
replication. Vif binds to the APOBEC3G molecules and eliminates APOBEC3G from 
producing cells through proteasomal degradation. 
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is not the only determinant of its antiviral activity (66–68). Deaminase-independent 
antiviral mechanisms, such as inhibition of tRNA primer annealing or strand transfer, 
may also play a role in the antiviral function of APOBEC3G (69, 70). 
In an evolutionary conflict, the viral Vif protein antagonizes APOBEC3G by 
inhibiting its packaging into viral particles and therefore allows production of virions 
free of APOBEC3G. This involves the degradation of APOBEC3G through a 
proteasome/ubiquitylation system (65, 71). Vif binds to APOBEC3G before it can be 
packaged into newly assembled virions. The ability of Vif to antagonize APOBEC3G is 
species-specific and is decided by how efficiently Vif binds to APOBEC3G. (68). Vif 
recruits the cellular proteins elongin B and elongin C, which then mediate cullin-5 
(CUL5)-ring-box-1 (RBX1)-dependent ligation of ubiquitins (Ub) to APOBEC3G. 
Ubiquitylated APOBEC3G is subsequently degraded by the proteasome (Figure 1-5) 
(65). However, a degradation-independent pathway was also suggested by observation 
that a Vif variant efficiently induced APOBEC3G degradation but was unable to restore 
viral infectivity (72).  
Although APOBEC3G expressed in target cells does not generally inhibit virus 
replication (57), studies have suggested that the expression of APOBEC3G in CD4+ T 
cells or monocytes/macrophages determines their permissivity to HIV-1 (22, 73, 137). 
Studies show that APOBEC3G is sequestered in an enzymatically active low-molecular- 
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Figure 1-5. The mechanism of Vif-dependent APOBEC3G degradation (65). Vif 
binds to APOBEC3G and recruits the cellular proteins elongin B and elongin C, which 
then mediate CUL5-RBX1-dependent Ubiquitylation of APOBEC3G. Ubiquitylated 
APOBEC3G is subjected to proteasomal degradation. 
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mass (LMM) ribonucleoprotein complex in resting CD4+ T cells or quiescent monocytes 
thus restricts infection of these cells by HIV-1. However, in activated CD4+ T cells or 
macrophages, cytoplasmic APOBEC3G resides in an enzymatically inactive 
high-molecular-mass (HMM) form (22, 74, 137) that allows HIV-1 infection. Whether 
deamination is required for APOBEC3G activity in these cells remains unclear (137).  
TRIM5α (Tripartite Motif-5α isoform) 
HIV-1 enters old world monkey cells efficiently but is restricted before reverse 
transcription (75, 76). A dominant negative factor TRIM5α confers the post entry block 
to HIV-1 in old world monkey cells (51). HIV-1 replication is restricted efficiently by 
TRIM5α derived from rhesus macaques and TRIMCyp from owl monkeys, but is less 
sensitive to TRIM5α from humans. SIV, which naturally infects old world monkeys, is 
less sensitive to restriction by rhesus monkey TRIM5α. Murine leukemia virus (MLV) is 
not restricted by rhesus TRIM5α, however, human TRIM5α efficiently restricts MLV 
(50, 51, 77). These studies revealed the restriction activities of TRIM5α and its 
homologues derived from primate are species-specific.  
TRIM5α is a trimeric cytoplasmic protein belonging to the TRIM (TRIpartite 
Motif) family, which was first identified by Reddy in 1992 as proteins containing a 
RING domain, a B-box, and a coiled-coil region (78). TRIM5α is an isoform containing 
a  carboxy-terminal SPRY  (B30.2)  domain (Figure 1-6).  The coiled-coil  domain  is 
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Figure 1-6. The structure of TRIM5α and the mechanism of TRIM5α-mediated 
lentivirus restriction (79). (A) The structure of TRIM5α is composed of a RING 
domain, a B-box, a coiled-coil region and a carboxy-terminal B30.2 domain. (B) The 
mechanism of TRIM5α-mediated restriction. After virus binding and fusion with host 
cells, viral core disassembles and viral RNA is released for reverse transcription. The 
CA proteins on viral core are targeted by TRIM5α thus leading to accelerated uncoating. 
As a result reverse transcription is compromised. 
 20
necessary for TRIM5α multimerization and is required for anti-viral restriction. The 
sequence in the SPRY domain is highly variable and contributes to the species-specific 
restriction, while in the TRIMCyp isoform from owl monkeys, this region is substituted 
by a CypA domain (50, 80–82). A single amino acid change (Arginine 332) in this 
region has been reported to determine the differential ability of human and monkey 
TRIM5α to restrict HIV-1 replication (83, 84). The B-box domain is suggested to 
mediate TRIM5α self-association which is important for the efficient binding of 
TRIM5α to the retroviral CA proteins (85). 
TRIM5α-mediated restriction occurs post entry and through interaction with viral 
CA proteins. SIV containing HIV-1 CA has been shown to be sensitive to the block in 
old world monkey cells, while HIV-1 containing SIV CA is less sensitive to the block in 
old world monkey cells (86 ). The expression of TRIM5α induces a decrease of 
particulate CA and sometimes an increase of soluble CA in the cytosol. This suggests 
TRIM5α specifically recognizes the CA proteins and promotes the rapid, premature 
disassembly of viral core, thereby inhibiting reverse transcription (82) (Figure 1-6). 
Studies have demonstrated that the TRIM5α ring finger has an E3 ubiquitin ligase 
activity in vitro and in vivo. A mutation in this domain decreases the restriction by 
TRIM5α and the treatment with proteasome inhibitors removes the restriction. These 
results indicate the possible involvement of ubiquitin in TRIM5α-mediated restriction 
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(87–90). In addition, studies have suggested that TRIM5α may block HIV-1 infection 
at nuclear import, and may function at later stages of the viral life cycle by degradation 
of viral Gag polyproteins  (91–93). 
Tetherin 
Vpu is an accessory protein unique to HIV-1, SIVCPZ, SIVGSN, SIVMUS, SIVMON 
and SIVDEN. There is no similar gene in HIV-2, SIVSM or other SIVs. Vpu is a dimeric 
integral membrane protein of 81 amino acids. Vpu mediates degradation of CD4 in the 
endoplasmic reticulum and regulates HIV-1 replication at late stages of the viral life 
cycle (32, 94, 95). 
The influence of Vpu is cell-type specific, suggesting involvement of a cellular 
factor. Using a cell fusion strategy, non permissive cells were found to express a cellular 
restriction factor and cause the retention of viral particles (96). In 2008, this restriction 
factor was identified as Bone marrow stromal cell antigen 2 (BST-2)/CD317 termed 
tetherin (31, 97). The expression of tetherin is cell type dependent and is part of the 
interferon induced antiviral defense system (31, 97, 98). Upon treatment with interferon, 
cells that are Vpu-independent become Vpu-dependent for efficient viral release (98). 
Tetherin prevents the release of virions from the cell membrane. In the absence of Vpu, 
viral particles produced from tetherin-expressing cells complete membrane fusion at the 
plasma membrane. However, these virions are retained at the cell surface where they 
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accumulate and are subsequently transported to endosomes (99).  
Tetherin prevents HIV-1 particle release by directly tethering virions to cells (100). 
Other than HIV-1, tetherin affects a large diversity of enveloped viruses including 
retroviruses (31, 97), filoviruses (Ebola) (98, 101), arenaviruses (102) and herpes 
viruses (103), indicating a common mechanism for tetherin-virion interaction. Tetherin 
protein has an N-terminal transmembrane (TM) domain and a C terminal 
glycosylphosphatidylinositol (GPI) lipid anchor ( 104 ). Additionally there is an 
extracellular domain that is predicted to form a coiled coil between the two membrane 
anchors (100). The tetherin molecules are anchored to the viral envelope and the cell 
membrane, associating through the coiled coil domain and thus prevent virions from 
detaching (31, 100). Virions trapped at the cell surface are eventually internalized for 
degradation. This is supported by the observation that with protease treatment, the 
attached virions can be released from cell surface (98, 99). An artificial tetherin protein 
assembled from fragments of heterologous proteins inhibited the release of HIV-1 and 
Ebola viruses. This confirmed the above model and demonstrated that the overall 
configuration of tetherin, rather than the specific sequence of the protein, is required for 
its antiviral activity (100). The exact role of each domain and how tetherin ‘tethers’ 
virions to the cell membrane remains unclear. Studies on tetherin mutants favor a model 
in which tetherin molecules form a dimer through the coiled coil domains, and the TM 
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domains of the dimer are incorporated into the virion envelope, while the GPI domains 
are anchored to the host-cell membrane (Figure 1-7) (100). 
How Vpu counteracts tetherin and permits viral particle release remains unclear. 
Vpu expressed via transient transfection or in the context of viral genome was found to 
reduce tetherin expression in HeLa cells (97, 103). In addition, Vpu may block the 
incorporation of the tetherin TM domain into virion envelopes (100, 105). Vpu may also 
alter tetherin trafficking and thus interfered with the function of tetherin (106). 
1.3 Introduction to Vpx and Vpr Proteins 
In all HIV and SIV genomes, a central viral region overlapping the Vif and Tat 
open reading frames encodes at least one protein Vpr. Vpr is a nuclear protein of 
96-amino acid, with a molecular mass of 14-kDa (107). Vpr interacts with p6 of the Gag 
precursor and is incorporated into virions during viral particle production ( 108 ). 
Members of the HIV-2/SIVSM/SIVMAC lineage contain an additional gene termed Vpx, 
which was originally derived from the African green monkey vpr gene by an ancestral 
recombination event (38). Vpx is a protein of 16-kDa that is highly conserved among 
divergent isolates of HIV-2 and SIVSM (109, 110). 
Vpx and Vpr proteins share considerable sequence similarity. Both proteins are 
predicted  to  have  3  helices  (Figure 1- 8)  and   are   packaged   into   virions   through  
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Figure 1-7. Model of tetherin mediated inhibition of HIV-1 virion release (100). 
Tetherin molecules form a dimer through the coiled coil domain. This dimmer is 
anchored to the host cell membrane through the TM domains on the N terminal, and is 
anchored to the envelope of budding virions through the GPI domains, thus preventing 
viral particle release. 
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Figure 1-8. Predicted 3-helix structure of Vpx and Vpr. (A) NMR based structure of 
Vpr. The NMR-based 3D-structure of Vpr (1–96) is characterized by 3 helices and 
flexible N and C termini. Three α helices are presented in pink (17–33), blue (38–50) 
and orange (54–77). The loops and flexible N and C termini are presented in green (111). 
(B) The Vpx and Vpr sequence alignment was generated by Clustal W 2.0 with 
consensus secondary structure prediction. H represents helix. C represents random coil. 
E represents beta strand. 
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association with p6 region of the Gag polyprotein (112–114). The packaging of Vpx 
and Vpr proteins into virions indicates they may play a role in the early stages of virus 
life cycle proceeding de novo production of viral proteins. Despite the similarities, the 
functions of Vpr and HIV-2/SIVSM Vpx do not appear to be the same. 
Most of the information regarding the roles of Vpr and Vpx proteins in primate 
lentivirus replication has been derived from studies with HIV-1 Vpr. The Vpr protein of 
HIV-1 has been shown to promote the accumulation of cells in the G2 stage of the cell 
cycle (33, 34, 115, 116), and to associate with the DNA repair enzyme Uracil DNA 
glycosylase (UDG) (117). The ability of HIV-1 Vpr to induce cell cycle arrest requires 
its binding partner, the E3 ubiquitin ligase complex scaffolding factor, DDB1 
(118–122). In addition, Vpr has been shown to promote the infection of terminally 
differentiated macrophages and dendritic cells (33, 36, 37, 123, 124), possibly by 
mediating the nuclear import of the viral PIC (125). These HIV-1 Vpr-ascribed activities 
have been suggested to segregate between the Vpx and Vpr proteins of HIV-2/SIVSM. 
The Vpr protein of HIV-2/SIVSM induces cell cycle arrest and associates with UDG but 
is dispensable for macrophage infection, while Vpx neither induces cell cycle arrest nor 
associates with UDG (38, 39). However, Vpx is essential for infection of simian 
macrophages   by   SIV   in   vitro   ( Table 1-1 ).   Following   the   infection   of  simian  
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Vpr of HIV-1 Vpr of HIV-2/SIVSM Vpx of HIV-2/SIVSM 
G2 cell cycle arrest G2 cell cycle arrest No 
UDG association UDG association No 
Promote macrophage 
infection possibly by 
facilitating nuclear import of 
PIC 
No 
Promote macrophage 
infection possibly by 
facilitating nuclear import of 
PIC 
 
Table 1-1. Proposed functions of HIV-1 Vpr, HIV-2/SIVSM Vpr and HIV-2/SIVSM 
Vpx based on previous studies (38, 39). 
 28
macrophages by Vpx minus SIVSM, late cDNA products are reduced while 2-LTR 
circles, which are formed only after completion of reverse transcription, are absent (38, 
39). In vivo, Vpx is also indispensable for dissemination and pathogenesis of SIV in 
pigtailed macaques (40). 
Whether any of these activities relate to the functional role of Vpr/Vpx proteins in 
primate lentivirus replication is unclear. In order to understand the functions of the 
Vpr/Vpx proteins in macrophage infection, I have focused on Vpx because of its 
profound impact on macrophage infection. In addition, its effect can be studied 
independently of other Vpr/Vpx-assigned activities including UDG association and cell 
cycle arrest. The purpose of this study is to further investigate the function of Vpx in 
myeloid cells infected by lentiviruses, and the mechanisms by which Vpx enhances 
lentiviral replication. 
1.4 Monocyte Infection by HIV-1 
HIV-1 infects and replicates primarily in CD4+ T cells and tissue macrophages. 
However, peripheral monocytes may also serve as a HIV-1 reservoir in disease 
progression. Peripheral blood monocytes are vitally important cells in the immune 
system as the precursor cells to professional antigen presenting cells (APCs). CD14 is 
expressed on the cell surface of 80-90% of blood monocytes and monocyte-derived 
macrophages. CD14 is a lipopolysaccharide (LPS) receptor that constitutively expressed 
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during monocyte differentiation (126). Upon differentiation of quiescent monocytes to 
macrophages, the expression of a macrophage-specific transferrin receptor, CD71, 
increases (126). 
The frequency of monocyte infection by HIV-1 in vivo appears to be low. 
Monocytes are implicated as a viral reservoir based on the detection of infectious viruses 
from monocytes isolated from HIV-1 positive individuals on antiretroviral therapy. In 
some cases, infectious viruses can be recovered from monocytes upon appropriate 
stimulation, although these cells produced undetectable amounts of viral RNA (17, 19, 
20, 127). In addition, monocytes harbor latent HIV-1 proviral DNA during the disease 
progression in spite of antiviral therapy (128). A small population of monocytes which 
are CD16+ apprears to be more susceptible to infection and preferentially harbors HIV-1 
viruses in vivo (22). 
Although lentiviruses have evolved the ability to infect terminally differentiated 
macrophages, peripheral blood monocytes are highly refractory to lentivirus 
transduction in vitro (16, 129–134). Permissivity to HIV-1 infection is coordinated to 
the state of monocyte differentiation (126, 134, 135). The mechanisms underscoring the 
block to transduction of quiescent monocytes by lentiviruses are not well understood. A 
different set of factors has been proposed to regulate infection of quiescent monocytes 
by lentiviruses. G0 monocytes have low intracellular dNTP levels (126, 136), and this 
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has been proposed to limit the efficiency of viral cDNA synthesis in these quiescent cells. 
The cytidine deaminase APOBEC3G, which is a target of the viral accessory protein Vif, 
has been shown to influence the permissivity of quiescent lymphocytes and monocytes 
to HIV-1 infection (22, 137 , 138). The enzymatically active LMM APOBECEG 
complex, which is the exclusive form in quiescent cells, has been shown to restrict 
infection of quiescent monocytes by HIV-1 (22, 74, 137). In addition, studies suggest 
that naturally occurring anti-HIV micro-RNA (miRNA) suppress HIV-1 in peripheral 
blood mononuclear cells or purified monocytes (139–142). In this study, the hypothesis 
that a restriction prevents the in vitro transduction of quiescent monocytes by HIV-1 was 
examined. 
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CHAPTER II                                   
Materials and Methods 
2.1 Clones 
SIVSM clone PBj1.9 
The infectious molecular clone SIVSM PBj1.9 was used for SIV infection in this 
study. This clone, which is representative of the HIV-2/SIVSM group of viruses, is a 
primary isolate and was derived from short-term peripheral blood mononuclear cell 
(PBMC) cultures (143). Unlike many other HIV-2 and SIVSM clones, PBj1.9 has a 
complete set of uninterrupted accessory genes and replicates efficiently in macrophages 
and represents a physiologically relevant virus strain. Mutants with deletion of Vpx or 
Vpr were constructed by Dr. Mark Sharkey as previously described (38). GFP (green 
fluorescent protein) expressing variants of wild-type and ΔVpx SIV contain an EGFP 
gene inserted between Bst 1107I sites within the viral envelope gene.  
HIV-1 clones 
NL43 is a CXCR4 tropism HIV-1 strain. This clone was derived from Full-length, 
replication and infection competent chimeric DNA, in which the 5´ fragment of proviral 
NY5 and the 3´ fragment of proviral LAV were cloned into pUC18 after removal of 
polylinker sites (144). In most experiments, wild-type and ΔVpr HIV-1 variants were 
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studied in the context of HIV-1 NL43. NL43ΔVpr clone was constructed by PCR based 
mutagenesis to generate mutation on start codon and to introduce early stop codons. 
NL43 GFP (a gift from Dr. Paul Clapham) contains an EGFP gene inserted between the 
envelope stop codon and nef within the HIV-1 NL43 backbone. 
ADA is a R5 HIV-1 strain originally isolated from a seropositive AIDS patient.  
LAI is an X4 HIV-1 strain which is the first strain of HIV-1 isolated in the 
laboratory cultured from Human PBMCs or CEM cells 
NA20 B59 is a NL43 clone with highly macrophage-tropic envelope (a gift from 
Dr. Paul Clapham’s lab). R5 tropic NA20 B59 envelope was amplified from brain tissue 
of AIDS patients (145), and cloned into pNL43 backbone using a BbsI site at the start of 
the envelope and an XhoI site downstream from the 3′ end of the envelope. 
Chimeric clones between SIV and HIV-1 
In all HIV-1/SIVSM chimeras, SIVSM proviral sequence was from PBj1.9, HIV-1 
sequence was from NL43 clone. The different domains of NL43 were precisely 
substituted for the corresponding domains of PBj1.9. All the chimeric clones were 
created by overlapping PCR. 
NL43 (SIV-Vif-Env) and the Vpx-deleted variant: The fragment from vif to env 
of NL43 was replaced with the corresponding sequence from PBj1.9 to generate 
chimeric clone NL43 (SIV-Vif-EnvΔVpx). NL43 (SIV-Vif-EnvΔVpx) is the same 
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chimera with Vpx deletion, which was introduced by Vpx start codon mutation and early 
stop codons. All the mutations are silent mutations for vif gene. 
NL43 (SIV-Vif-Vpx) and the Vpx-deleted variant: the NL43 sequence from vif 
to vpr was replaced with the sequence of vif to vpx from PBj1.9 to generate NL43 
(SIV-Vif-Vpx) clone. NL43 (SIV-Vif-ΔVpx) is the chimera variant in which Vpx was 
deleted with the same strategy mentioned above. 
Vpx and M4 mutant 
The SIVSM Vpx gene was amplified from PBj1.9 proviral clone, and inserted into a 
pIRES2-EGFP vector (BD) either with or without a N-terminal minimum HA epitope. 
The upstream primer for each PCR product provided a Kozak sequence. The Vpx lysine 
mutant M4 was generated using Quikchange XL sitedirected mutagenesis (Stratagene). 
These clones were generated by Dr. Yuanfei Wu. 
DDB1-Vpr fusion 
The DDB1 gene was amplified and subcloned from pBj-hp125 (ATCC, MBA-126) 
and inserted into pIRES2-EGFP as an in frame fusion with the C-terminal of SIV Vpr. A 
Flag epitope was added to the N terminal of DDB1 as flanking sequences between Vpr 
and DDB1. As a control, an N-terminal Flag tagged DDB1 was inserted into 
pIRES2-EGFP. 
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Vpr expressing plasmid and primary Vpr expressing plasmid 
The HIV-1 Vpr was amplified from NL43 proviral clones, and inserted into a 
pIRES2-EGFP vector (BD). The primary Vpr sequences were derived from plasma 
samples of AIDS patients with high viral load (Courtesy from Dr. Katherine Luzuriaga’s 
lab). The RNA was extracted from the plasma sample and first strand DNA was 
synthesized. The primary Vpr region was amplified from DNA and cloned into 
pIRES2-EGFP vector to create the primary Vpr expressing vectors. 
2.2 Cell Culture 
293T, HeLa and COS-1 cells 
293T, HeLa, and COS-1 cells were maintained in DMEM containing 10% Fetal 
Bovine Serum (FBS). 
Macrophages 
Peripheral blood monocytes were obtained by elutriation and counter current 
centrifugation and maintained 2 days in DMEM containing 10% human serum and 
monocyte colony stimulating factor (MCSF) (RD Systems) and for a further 5 days in 
medium lacking MCSF prior to use in experiment.  
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Monocytes 
Human monocytes were obtained from healthy donors by countercurrent 
centrifugal elutriation (146). The monocytes were kept in DMEM containing 10% 
human serum and used freshly for infection. 
2.3 Production of Virus Stocks 
Unless indicated other way, viruses were pseudotyped with Vesicular Stomatitis 
Virus G envelope proteins (VSV-G). For the generation of viral stocks, 293T cells were 
transfected with proviral DNAs using a modified calcium phosphate/DNA precipitation 
method. Viruses were pseudotyped with VSV envelope glycoproteins by cotransfection 
of proviral DNAs with a plasmid expressing the VSV envelope glycoprotein. For 
encapsidation of wild-type and mutant Vpx and Vpr proteins, 293T cells were 
cotransfected with proviral DNAs and plasmids expressing Vpx and Vpr proteins. The 
DNA ratio for pVSV-G, proviral clones and pIRES2-EGFP-Vpx was 1:14:1. HIV-1 and 
SIV stocks were normalized on the basis of reverse transcriptase activity.  
Pseudotyped MLV (MLV-G) was prepared by Dr. Rajnish Kaushik. The stocks 
were obtained by transfecting retroviral-packaging 293A cells with pLEGFP-c1 and 
pMD-G. Viral particles in culture supernatants were harvested after 24 and 48 hours, 
passed through 0.45 mm filter and concentrated by ultra-centrifugation. 
All virus stocks were treated with DNaseI (Worthington, NJ, USA) to remove 
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residual transfection DNA.  
2.4 Infection  
For infection, macrophages or monocytes were plated in 24 well plates and 
infected with HIV-1 at 1 million RT units/well. After 4 hours, cells were washed with 
fresh medium and incubated at 37ºC for the remainder of the experiment.  
Pre-infection studies were performed by first infecting macrophages with 
pseudotyped wild-type SIV (SIVWT) or SIVΔVpx variants and 4 hours later, the 
supernatant was removed and the cells were inoculated with HIV-1 or MLV for another 
4 hours. The supernatant was removed and the cells were washed with fresh medium and 
incubated at 37ºC for the remainder of the experiment. At indicated time points after 
inoculation, the cells were lysed and DNA extracted from each sample for quantitative 
real time PCR. When indicator viruses were used for infection, the cells were checked 
under fluorescent microscope or the numbers of green cells were quantitated by flow 
cytometry.  
To control for the carry over DNA from virions, cells were treated with reverse 
transcriptase inhibitor Azidothymidine (AZT) 4 hours before infection at a final 
concentration of 10µM. The same concentration of AZT was kept during the whole 
experiment. 
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2.5 Analysis of Viral Infection by Quantitative PCR 
Viral infection efficiency was gauged from synthesis of viral cDNA products at 
early intervals (24 and 48 h) post-infection. Cells were initially infected with viruses. 
After 4 hours, cells were washed with fresh medium and incubated at 37ºC for the 
remainder of the experiment. Pre-infection studies were performed by first infecting 
macrophages with pseudotyped SIV wild-type or SIVΔVpx variants and 4 hours later, 
the cells were infected with HIV-1 or MLV for another 4 hours before washing cells 
with fresh medium. Infected cells were washed with PBS before harvesting samples for 
DNA analysis. Total DNA was extracted from infected cells using DNAzol reagent 
(Invitrogen).  
Quantitative analysis of viral cDNA intermediates is as described (38, 147, 148), 
and primers and probes for quantitative PCR are listed in table 2-1. Copy number 
estimates of cDNA and 2-LTR circles were determined on an ABI Prism 7500 fast 
machine. The real-time PCR analysis from each sample was carried out in duplicate 
wells and most of the values shown in the figures are average of independent 
experiments using macrophages from at least 3 different donors. Viral cDNA was 
expressed on a per cell basis after quantitation of cellular CCR5. 
2.6 Proteasome Inhibition 
Macrophages in 24 well plates were directly infected with VSV-G-pseudotyped  
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PBj1.9 late products (Plus strand extension) 
PBj1.9 late f AAGCCAGTGTGTGTTCCCATC U5 
PBj1.9 late r CATCTGCTTTCTTCCCTGACAA Gag
PBj1.9 late prb 6-FAM-CCTAGCCGCCGCCTGGTCATCT- Iowa Black FQTM 
U5 
PBj1.9 2-LTR circles 
pBj4n/f  AGAAGCCCCTGGTCTGTTAGGAC U5 
pBjC/r TCGTCTTCCTGAGCTTCATCTGA U3 
PBj1.9 probe 6-FAM-TGGCAAAATTACACAGCAGGGCCAG-Iowa Black FQTM 
U3 
HIV late products (Plus strand extension) 
C1/f TAGACCAGATTTGAGCCTGGGA R 
LAI 7/r TCTCCTTCTAGCCTCCGCTAGTCAA GLS
2nr4nr 6-FAM-AGCCTCAATAAAGCTTGCCTTGAGTGC-Iowa Black FQTM 
R 
HIV 2-LTR circles 
C1/f TAGACCAGATCTGAGCCTGGGA R 
C4/r GTAGTTCTGCCAATCAGGGAAG U3 
2nr4nr 6-FAM-AGCCTCAATAAAGCTTGCCTTGAGTGC-Iowa Black FQTM 
R 
MLV late products (Plus strand extension) 
OJWB45 GCGCCAGTCTTCCGATAGACTG R 
OJWB48 ACAATCGGACAGACACAGATAAGTTG Gag
OJWB38 6-FAM-ATCCGAATCGTGGTCTCGCTGTTC-TAMRA R 
MLV 2-LTR circles 
OJWB45 GCGCCAGTCTTCCGATAGACTG R 
OJWB46 GGGCTCTTTTATTGAGCTCGGAG U3 
OJWB38 6-FAM-ATCCGAATCGTGGTCTCGCTGTTC-TAMRA R 
Macrophage CCR5 
CCR5/r CTCACAGCCCTGTGCCTCTTCTTC  
CCR5/f GCTGTCTTTGCGTCTCTCCCAGGA  
CCR5 probe  6-FAM-AGCAGCGGCAGGACCAGCCCCAAG-Iowa Black FQTM 
 
Table 2-1. Primers and probes for quantitative real-time PCR. 
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viruses (1 million RT/well) in the presence of proteasome inhibitors including 
Lactacystine (10 µM), ALLN (50 µM) or Proteasome inhibitor 1 (50µM). After 3–5 
hours, supernatant was removed and replaced with fresh medium containing proteasome 
inhibitors. After 24 and 48 h postinfection total DNA was isolated using DNAzol 
reagent (Invitrogen) and analyzed by real-time PCR assay for 2-LTR circles. 
2.7 COS-Macrophage Cell Staining and Cell Fusion 
For FACS analysis, COS cells and human macrophages were stained with 3.5 mM 
CellTracker Green CMFDA (5-chloro methylfluorescein chloromethyl- fluorescein 
diacetate) and 24 mM CellTracker Blue CMAC (7-amino-4- chloromethylcoumarin), 
respectively. For fluorescence microscopy, COS cells and macrophages were stained 
with 2.5 mM DiO (3,39-dioctadecyloxacarbo cyanine perchlorate) and 12 mM DiI  
(1,19-dioctadecyl-3,3,39,39- tetramethylindo- carbocyanine perchlorate) respectively, 
according to manufacturer’s instructions (Molecular Probes). 
Generation of macrophage homokaryons was achieved by polyethylene glycol 
(PEG). Briefly, labeled cells, 15×106 each group, were mixed and centrifuged at 250 g. 
50% PEG-1450 was added dropwise to the pellet and cells incubated for 2 min at 37ºC 
with gentle mixing. 1 ml PBS was then added dropwise to the cells over 1 min, followed 
by 3 ml of 2% FBS/PBS over another 2 minutes. Cells were washed 3 times with 2% 
FBS/PBS and plated in a 100 mm culture dish (1×107 cells/dish). COS-macrophage and 
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COS-COS cell fusion was achieved using paramyxovirus hemagglutinin-neuraminidase 
(HN) protein and fusion (F) protein. Briefly, COS cells were transfected with 
pCAGGS-HN and pCAGGS-F expression vectors encoding HN and F proteins of 
Newcastle disease virus (gift of Prof. T. Morrison) (149). Sixteen to twenty hours 
post-transfection, COS cells were stained, mixed with stained macrophages (ratio 1:1.5) 
and plated in 100 mm dishes. COS homokaryons were generated at 1:1 ratio. After 
overnight incubation, cells were infected with either SIV wild-type or SIVΔVpx for 24 h. 
Cell sorting was performed with a FACSAria flow cytometer using the FACSDiva 
software (Becton Dickinson). Double-stained cells were sorted. Total DNA was isolated 
using DNeasy Blood and Tissue Kit (Quiagen) and analyzed by realtime PCR assay for 
2-LTR circles. 
2.8 HeLa-Monocyte Cell Staining and Cell Fusion 
HeLa-monocyte fusion was achieved using a GenomeONE-CFEX HVJ envelope 
fusion kit (Cosmo Bio Co., Ltd.). Manufacturer’s instructions for fusion in suspension 
were followed. Briefly, GFP-expressing HeLa were mixed with monocytes (ratio 1:6) 
and incubated in the presence of HVJ-E suspension (1.25 ul/1x 106 cells) on ice for 5 
min and subsequently at 37ºC for 15 min. Cells were plated in 100 mm dishes and 
infected with HIV-1NL43 Luc or SIVWT for 40 hours. Prior to cell sorting, cells were 
stained with an APC-conjugated antibody to CD14 (BD Biosciences). Heterokaryons 
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were sorted based on GFP and APC double staining. HIV-1 NL43 Luc infection was 
measured by quantifying luciferase activity. 
2.9 Virion Precipitation, Protein Purifications and Western Blotting  
Supernatants from 293T cells transfected with infectious molecular clones were 
cleared of cellular debris by low-speed centrifugation (1500g, 10 min) and then filtered 
(0.45 µm). Virions in clarified supernatants were concentrated at 10,000 g for 2 h with 
20% sucrose cushion. The supernatants were removed and the virus pellets were lysed in 
RIPA buffer (50 mM Tris-Hcl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% NaDoc, 0.1% 
SDS and protease inhibitor cocktail). The cells were also lysed in RIPA buffer and 
clarified by centrifugation at 14,000 rpm for 15 min. Lysates of transfected cells or 
purified virions were boiled in sample buffer, resolved by SDS/ PAGE and Western 
blotted. The presence of encapsidated Vpx proteins was examined by an anti-HA 
antibody (HA, 16B12, Covance).The presence of viral Capsid was examined by 
anti-Capsid antibody (polyclonal, ABI). 
2.10 Analysis of Vpx Ubiquitylation 
293T cells were co-transfected with HA-Vpx, HA-Vpx lysine mutants or a 
pIRES2-EGFP empty vector and pRGB4-6His-myc-Ubiquitin at a 1:4 ratio using 
lipofectamine 2000 (Invitrogen). Non-6His tagged Ubiquitin was included as a control 
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for Ni-NTA pull-down. 36 h after transfection, the 6His-ubiquitin conjugated proteins 
were purified using Ni-NTA Magnetic Agarose beads (Qiagen) under native conditions 
(150). Briefly, cells were lysed in detergent buffer (10 mM Tris-Hcl pH7.5, 150 mM 
NaCl,1% Triton X-100 and protease inhibitor cocktail) and clarified by centrifugation at 
14,000 rpm for 15 min. The cell lysates were incubated with Ni-NTA beads overnight at 
4uC in detergent buffer with 300 mM NaCl, 20 mM imidazole and 5 mM MG132. The 
beads were washed in lysis buffer and attached proteins were eluted in elution buffer (50 
mM NaH2PO4, 375 mM NaCl, 1% Triton, 250 mM imidazole pH 8.0). 
2.11 RNA interference of DDB1 
The siRNA sequences for DDB1 silencing in macrophages, COS-1 or 293T cells were 
siRNA1: GCAAGGACCTGCTGTTTAT 
siRNA2: GCATGCCAGCATTGACTTA 
siRNA3: CCTGCATCCTGGAGTATAA 
The Scrambled control siRNA sequence was CAGTCGCGTTTGCGACTGG 
Macrophages or COS-1 cells were transfected twice with 60 pmol each siRNA using 
lipofectamine 2000. 24 h after siRNA transfection, cells were infected with 
RT-normalized viruses as indicated. The DDB1 protein knockdown levels were 
examined at the same time point as cDNA analysis.  
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2.12 Vpx-DDB1 co-immunoprecipitation 
293T cells were transfected with Flag-Vpx, Flag-Vpx lysine mutant (VpxM4) or 
pIRES2-EGFP vector. 36 h after transfection, cells were harvested and lysed in Co-IP 
lysis buffer (100 mM NaCl, 50 mM Tris-Hcl pH 7.5, 5 mM MgCl2, 0.5% NP-40, 
protease inhibitor cocktail) and incubated with Protein A and Protein G beads 
(Invitrogen) conjugated anti-Flag M2 antibody overnight at 4uC. The beads were 
washed 4 times in a more stringent wash buffer (400 mM NaCl, 50 mM Tris-Hcl pH 7.5, 
5 mM MgCl2, 0.5 % NP-40, and protease inhibitor cocktail). And bound proteins were 
boiled and eluted in 26 Laemmli’s SDS sample buffer. 
2.13 Dose Dependent Analysis of Vpx 
293T cells were co-transfected with ΔVpx PBj1.9 proviral DNA (9µg) and 
increasing amount of plasmid expressing Vpx, or empty plasmid. Wild-type PBj1.9 was 
used as a positive control. All viruses were pseudotyped with VSV envelope 
glycoprotein. Viral infection efficiency was gauged from synthesis of viral 2-LTR cDNA 
products at 24 and 48 h post-infection. Viral cDNA copies were normalized with CCR5 
copy numbers. Virions were harvested from supernatant through sucrose density 
centrifugation and lysed in RIPA buffer. Lysed virions were resolved by SDS/PAGE and 
western blotted with anti p27 or anti Vpx antibody. The integrated density was measured 
by Scion Image software. 
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2.14 FACS and Monocyte/Macrophage Immunophenotyping 
Expression of CD14, CD71, or GFP in monocytes/macrophages was monitored by 
flow cytometry. Cells were collected day 0 to day 6 post-infection and washed twice 
with buffer (PBS containing 0.1% fetal bovine serum and 2 mM EDTA). The washed 
cells were incubated with an antibody mixture containing PE conjugated anti-human 
CD14 (BD Biosciences) and APC conjugated anti-human CD71 (BD Biosciences) for 40 
min. Cells were rinsed twice with washing buffer and fixed with 1% paraformaldehyde. 
Fixed cells were analyzed by cell flow cytometry analysis using a FACSCalibur System 
(BD Biosciences) and analyzed with Flowjo software (Tree Star, Inc). The percentage of 
infected CD71– monocytes and CD71+ macrophages were determined from the 
percentages of GFP+/CD71– or GFP+/CD71+ cells, respectively. 
2.15 APOBEC3G Analysis 
H9 cells, monocytes or macrophages were washed twice with PBS and incubated 
with lysis buffer containing 50 mM HEPES pH 7.4, 125 mM NaCl, 0.2% NP-40 and 
EDTA-free protease inhibitor cocktail (Roche). Cell lysates were clarified by 
centrifugation at 14000 rpm for 30 min at 4ºC (Microfuge 22R, Beckman Coulter). 
Cleared cell lysates were quantitated (Protein assay kit, Bio-Rad) and analyzed by Fast 
Performance Liquid Chromatography (FPLC). For RNase treatment of HMM complexes 
from H9 cells, cell lysates was incubated with 50 μg/ml RNase A (Roche, DNase-free) at 
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room temperature for 1h before analysis by FPLC. FPLC was run on an ÄKTA™ FPLC 
using a Superose 6 10/300 GL gel filtration column (GE healthcare). The running buffer 
contained 50 mM HEPES pH 7.4, 125 mM NaCl, 0.1%NP-40, 1mM DTT and 10% 
Glycerol. Fraction size was set at 1ml. 20 μl of each fraction was boiled with Laemmli’s 
23 SDS-sample buffer (6xreducing, BOSTON Bioproducts) and loaded onto a 10% 
SDS-PAGE. Proteins were transferred to nitrocellulose membranes and blotted with 
rabbit anti-APOBEC3G antibody (Courtesy of Dr. Tariq Rana) using a TROPIX 
CDP-star system (PerkinElmer). 
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CHAPTER III                                  
Vpx Promotes Macrophage Infection by HIV-1 and MLV 
3.1 Chapter Summary 
This chapter presents evidence that a restriction in macrophages potently 
antagonizes infection of macrophages by SIV. Vpx was required for macrophage 
infection by SIVSM. Viral cDNA production was reduced dramatically in macrophages 
infected with an SIVSM variant lacking Vpx. However, infection of COS or HeLa cells 
with wild-type or Vpx-deleted SIVSM resulted in comparable cDNA levels. This suggests 
the existence of a cellular factor that regulates SIVSM infection. To determine if COS 
cells contain a positive factor which is activated by Vpx, or if macrophages contain a 
negative factor which is counteracted by Vpx, heterokaryons between permissive COS 
cells and nonpermissive macrophages were generated. Macrophage/COS heterokaryons 
remained resistant to SIVΔVpx infection, indicating that macrophages harbored a 
dominant antiviral restriction that is counteracted by the Vpx protein and that this 
restriction is absent from COS cells. 
Using an HIV-1 chimera containing SIVSM Vpx, I demonstrated that the antiviral 
restriction that antagonized SIVSM infection of macrophages was active against HIV-1. 
Furthermore, neutralization of this restriction by encapsidating Vpx into HIV-1 virions 
or by preinfecting macrophages with wild-type SIV dramatically enhanced HIV-1 
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infection in macrophages, confirming the susceptibility of HIV-1 to this restriction. This 
also indicated that Vpx functioned in the target cells shortly after infection and that a 
small amount of Vpx was sufficient to neutralize the restriction. Packaging of Vpr in 
trans failed to enhance HIV-1 infection in macrophages, supporting that the 
neutralization activity is specific for Vpx. 
Macrophages are refractory to transduction by gammaretroviruses such as MLV. To 
determine whether the same restriction is an obstacle to transduction of macrophages by 
MLV, I examined whether neutralization of the restriction would render macrophages 
permissive to MLV. Macrophages preinfected with wild-type but not Vpx-deleted SIV 
were permissive to MLV transduction. This suggests that Vpx delivered to macrophages 
removes the block to MLV and that the same restriction that antagonizes SIV/HIV-1 
infection of macrophages also antagonizes MLV.  
In summary, our results indicate that macrophages harbor a restriction that 
antagonizes SIV, HIV-1, and MLV at the level of reverse transcription. The Vpx protein 
of HIV-2/SIVSM specifically overcomes this restriction. Therefore, the relative ability of 
lentiviruses and other retroviruses such as MLV to transduce macrophages is partially or 
fully dependent upon their ability to neutralize this cellular restriction. 
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3.2 SIVSM Vpx but not Vpr is Required for Infection of Human Macrophages by 
SIVSM.  
Previous publications have demonstrated that Vpx of HIV-2/SIVSM was essential 
for early events in SIVSM infection of macaque macrophages yet dispensable for 
infection of macaque PBMCs or CEM174 cells (38). The first experiment examined 
whether Vpx or Vpr was required for SIVSM infection of human macrophages and cell 
lines. Vpx function was studied in the context of SIVSM PBj which represents a primary 
isolate (143). To increase particle infectivity and facilitate analysis of early events in the 
viral life cycle, viruses were pseudotyped with VSV-G envelope proteins. Although 
VSV pseudotyping has been shown to alleviate the defects exhibited by other accessory 
gene mutants such as Nef, pseudotyping did not alleviate the infectivity defect of 
Vpx-deleted viruses in macrophages.  In order to gauge infection of primary 
macrophages under single cycle conditions, viral cDNAs (mainly 2-LTR cDNA) were 
quantitated by real time PCR.  
The profound requirement for Vpx but not Vpr in macrophage infection by SIVSM 
is illustrated in Figure 3-1A. 2-LTR cDNA is formed only after completion of viral 
reverse transcription and translocation of viral cDNA to the nucleus where 
circularization occurs. Levels of 2-LTR cDNA in macrophages infected with a wild-type 
SIV and an SIV variant lacking  Vpr  were  indistinguishable  (Figure 3-1A).  In contrast,  
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Figure 3-1. Differential susceptibility of macrophages and cell lines to infection by 
wild-type and Vpx-deleted (ΔVpx) or Vpr-deleted (ΔVpr) variants of SIVSM. (A)The 
profound requirement for Vpx but not Vpr in macrophage infection by SIVSM Virus 
infection was gauged from the levels of viral 2-LTR cDNA at 24 and 48 hours 
post-infection. SIV cDNA copy number was normalized to cell number based on CCR5 
copy number. (B) Susceptibility of COS or HeLa cells to infection by wild-type, ΔVpx 
and ΔVpr SIVSM. 
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there is a profound block to infection of macrophages by Vpx-deleted SIV at the level of 
reverse transcription. Viral 2-LTR cDNA was reduced at least 100 fold in macrophages 
infected with an SIV variant lacking Vpx (Figure 3-1A). In COS cells and in HeLa cells, 
viral cDNA synthesis with wild-type and Vpr-deleted or Vpx-deleted viruses were 
similar (Figure 3-1B). Our original study on the requirement for Vpx in SIV infection of 
monkey macrophages reported a significant defect in 2-LTR circle formation using non 
quantitative PCR (38). This is consistent with the defect observed in this study which 
involves infection of human macrophages with SIV. These results suggest that Vpx 
protein is required for SIVSM infection in macrophages, but is dispensable for SIVSM 
infection of COS and HeLa cells. 
3.3 Macrophages Harbor a Restriction Factor that is Counteracted by the Vpx 
Protein  
Although Vpx was necessary for macrophage infection, Vpx was dispensable for 
infection of COS/ HeLa cells. This suggested the existence of cellular activities, 
differentially expressed between macrophages and COS cells or HeLa cells, which 
impact primate lentivirus infection. One possibility was that COS and HeLa cells contain 
a cellular activity that promotes virus infection. But in macrophages, this activity must 
be activated by the Vpx protein. An alternative possibility was that macrophages contain 
a cellular restriction to infection that is counteracted by the Vpx protein and this cellular 
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restriction is not expressed in COS or HeLa cells. To distinguish between these two 
possibilities, a strategy previously adopted to characterize the mechanism by which Vif 
promotes viral infection was used (151, 152). 
Heterokaryons were generated between macrophages and COS cells and the 
susceptibility of the heterokaryons to infection by wild-type SIV and SIVΔVpx was 
compared. When the fusogenic proteins of Newcastle Disease Virus (NDV) were 
expressed in COS cells, these cells readily underwent fusion with primary macrophages 
(Figure 3-2A). Macrophage/COS heterokaryons (double staining cells) were isolated by 
fluorescence-activated cell sorting (FACS). Double staining cells were not observed 
when normal COS cells (not expressing NDV proteins) were mixed with macrophages 
(Figure 3-2B). As an additional control, macrophage homokaryons were produced using 
polyethylene glycol (PEG). Both macrophage/COS heterokaryons as well as COS and 
macrophage homokaryons were infectible by wild-type SIV (Figure 3-2C). In contrast, 
macrophage homokaryons and macrophage/COS heterokaryons were resistant to 
SIVΔVpx infection (Figure 3-2C). Since fusion with COS cells did not relieve the block 
to macrophage infection by SIVΔVpx, this indicated that macrophages harbor an 
antiviral restriction which is counteracted by the Vpx protein and this restriction is 
absent from COS and Hela cells (Figure 3-3). 
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Figure 3-2. Vpx antagonizes an antiviral restriction in macrophages. (A) 
Heterokaryons were formed between primary macrophages and between COS cells 
expressing fusogenic HN and F proteins of Newcastle Disease Virus. To visualize 
heterokaryons by fluorescence microscopy, COS cells were stained with DiO (green) 
and macrophages were stained with DiI (red). (B) FACS analysis of macrophage-COS 
heterokaryons. COS cells were cotransfected with NDV HN and F expression vectors 
(COS-NDV) or with empty, control vectors (COS). COS cells were stained with 
CellTracker Green CMFDA and macrophages were stained with CellTracker Blue 
CMAC. Double-stained cells were sorted as indicated by the gate. (C) Susceptibility of 
macrophage/COS heterokaryons and COS and macrophage homokaryons to infection by 
SIVWT and SIVΔVpx virus variants. Infection was gauged from levels of late cDNAs 
and 2-LTR circle cDNAs. 
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Figure 3-3. Model of the function of Vpx in SIVSM infection of macrophages. 
Macrophages harbor an antiviral restriction blocking SIVSM infection before completion 
of reverse transcription. This restriction is counteracted by Vpx protein. 
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3.4 HIV-1 Vpr is Dispensable for HIV-1 Reverse Transcription in Macrophages  
HIV-2, SIVSM and SIVMAC encode both Vpx and Vpr proteins. However, Vpr is 
the only accessory protein in HIV-1 that is closely related to Vpx. Previous studies from 
our group demonstrate that Vpr proteins of HIV-2/SIVSM induce cell cycle arrest and 
associate with UDG, but are dispensable for macrophage infection in vitro. Vpx neither 
induces cell cycle arrest nor associates with UDG, but is required for SIV infection in 
macrophages (38, 39, 40). This suggests that HIV-1 Vpr-ascribed activities segregate 
between the Vpx and Vpr proteins of HIV-2/SIVSM (38). I next sought to determine if 
HIV-1 Vpr has the ability to overcome the restriction factor in macrophages.  
Vpx-deleted SIVSM was fully attenuated in macrophages, thus whether Vpr-deleted 
HIV-1 was also attenuated in macrophages was examined. Two HIV-1 strains, LAI and 
NL43 were used in this study. The transduction efficiency of wild-type or Vpr-deleted 
HIV-1 in macrophages was similar, when gauged by the level of 2-LTR circles (Figure 
3-4). This suggests that HIV-1 Vpr is dispensable for infection of macrophages at the 
level of reverse transcription. 
The observation that both wild-type and Vpr-deleted HIV-1 were comparable in 
single round infection in macrophages can be explained by two possibilities. One 
possibility is that HIV-1 is not blocked by the same restriction factor that blocks SIVSM 
infection in macrophages.  Therefore, the deletion of Vpr has no effect on HIV-1 2-LTR 
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Figure 3-4. Vpr is dispensable for HIV-1 infection of macrophages at the level of 
reverse transcription. Macrophages were infected with wild-type or Vpr-deleted HIV-1. 
Both LAI (upper panel) and NL43 (lower panel) strains were used for this study. Virus 
infection was gauged from the levels of viral 2-LTR circles at 24 and 48 hours post 
infection. 
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level. Another possibility is that HIV-1 is partially restricted by the same restriction 
factor, but HIV-1 Vpr is not able to overcome this restriction. This would account for the 
indistinguishable infectivity between wild-type and Vpr-deleted HIV-1 in macrophages.  
3.5 The Antiviral Restriction Which Antagonizes SIVSM Infection of 
Macrophages is Active against HIV-1 
A significant defect in 2-LTR circle synthesis was observed in macaque and human 
macrophages infected with Vpx-deleted SIV. In contrast to SIV, wild-type or Vpr-deleted 
HIV-1 infected human macrophages to a similar level, as evidenced by comparable 
levels of 2-LTR circle production. Based on these observations, it was initially assumed 
that HIV-1 was not affected by the macrophage restriction. If SIVSM is restricted in 
macrophages while HIV-1 is not, replacing the viral component that is targeted by the 
restriction in SIVSM with the corresponding sequence from HIV-1 would rescue 
SIVSMΔVpx infection of macrophages. The same strategy was used to identify CA as the 
target of TRIM restriction (86). 
The Gag-Pol products of primate lentiviruses function at several different steps of 
the lentivirus life cycle. I first examined whether SIVSM Gag-Pol products are involved 
in determining the antiviral restriction in macrophages. Chimeras between HIV-1 and 
SIVSM were generated with sequences of MA, CA, NC, p6, PR or RT from HIV-1 
inserted into the corresponding region of  the  SIVSM  backbone (Figure 3-5).  All the 
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HIV-1 
SIVSM 
 
Figure 3-5. Structure of chimeric clones between HIV-1 and SIVSM. The SIVSM 
PBj1.9 isolate and HIV-1 NL43 were used to create these chimeric constructs. The 
different domains of NL43 were precisely substituted for the same domain in the PBj1.9 
proviral clone. Sequences from SIVSM were shown in white, while the black area 
represented components from HIV-1 that were inserted into the corresponding region of 
the SIVSM proviral clone. Vpx-deleted variant of each chimera was also constructed. 
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chimeras in this study were created by overlapping PCR. The chimeric SIVSM containing 
p6 and PR from HIV-1 were replication-defective in COS cells that support SIV ΔVpx 
replication. The Vpx-deleted chimeric viruses with MA, CA, NC or RT replaced were 
capable of single round infection in COS cells. However, those viruses were restricted in 
macrophages (Figure 3-6 to Figure 3-9), suggesting that the substituted viral components 
were not the target of the macrophage restriction. 
I next examined whether the target of the restriction was located on the 5’ half or 
3’ half of the SIVSM genome. Additional chimeric viruses were constructed with an 
HIV-1 backbone containing the 3’ half of the SIVSM genome (Figure 3-10). The 
junctions between SIVSM and HIV-1 were located at the beginning the vif gene and the 
end of the env gene. In this chimeric NL43 (SIV-Vif-Env), the LTR and the gag-pol 
sequences were derived from the HIV-1 clone NL43. Vif (including a small overlapping 
region between pol and vif), vpx, vpr, env, tat and rev genes were derived from the SIVSM 
clone PBj1.9 (Figure 3-10). The Vpx-deleted variant of this chimera was created by 
mutating the vpx start codon and introducing an early stop codon (Figure 3-10). The 
mutations introduced were silent mutations for vif gene. The susceptibility of COS cells 
and macrophages to HIV-1/SIVSM chimeric virus infection was examined. The 
infectivity of NL43 (SIV-Vif-Env) and the Vpx-deleted variant NL43 
(SIV-Vif-EnvΔVpx)  in  COS  cells  was  similar  when  gauged  by  HIV-1  cDNA levels,  
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Figure 3-6. Vpx is required for SHIV-MA infection of macrophages. (A) A 
schematic of chimeric proviral clone with SIV backbone and MA from HIV-1 
(SHIV-MA) and the Vpx-deleted variant (SHIVΔVpx-MA). (B) Susceptibility of COS 
cells to infection by SHIV-MA chimera and Vpx-deleted variant SHIVΔVpx-MA. COS 
cells were infected and virus infection was gauged from the levels of viral 2-LTR cDNA 
at 24 and 48 h post-infection. (C) Susceptibility of macrophages to infection by 
SHIV-MA chimera and Vpx-deleted variant.  
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Figure 3-7. Vpx is required for SHIV-CA infection of macrophages. (A) A 
schematic of chimeric proviral clone with CA and p2 from HIV-1 inserted into SIV 
backbone (SHIV-CA) and the Vpx-deleted variant (SHIVΔVpx-CA). (B) Susceptibility 
of COS cells to infection by SHIV-CA chimera and Vpx-deleted variant SHIVΔVpx-CA. 
(C) Susceptibility of macrophages to infection by SHIV-CA chimera and Vpx-deleted 
variant.  
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Figure 3-8. Vpx is required for SHIV-NC infection of macrophages. (A) A schematic 
of chimeric proviral clone with NC and p1 from HIV-1 inserted into SIV backbone 
(SHIV-NC) and the Vpx-deleted variant (SHIVΔVpx-NC). (B) Susceptibility of COS 
cells to infection by SHIV-NC chimera and Vpx-deleted variant SHIVΔVpx-NC. (C) 
Susceptibility of macrophages to infection by SHIV-NC chimera and Vpx-deleted 
variant. 
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Figure 3-9. Vpx is required for SHIV-RT infection of macrophages. (A) A schematic 
of chimeric proviral clone with RT from HIV-1 inserted into SIV backbone (SHIV-RT) 
and the Vpx-deleted variant (SHIVΔVpx-RT). (B) Susceptibility of COS cells to 
infection by SHIV-RT chimera and Vpx-deleted variant SHIVΔVpx-RT. (C) 
Susceptibility of macrophages to infection by SHIV-RT chimera and Vpx-deleted 
variant. 
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NL43 (SIV-Vif-Env)
NL43 (SIV-Vif-Env ΔVpx)  
 
HIV-1 
SIVSM 
 
Figure 3-10. A schematic of chimeric proviral clone NL43 (SIV-Vif-Env) and 
Vpx-deleted variant NL43 (SIV-Vif-EnvΔVpx). The fragment from vif to env of NL43 
was precisely substituted for the same domain in the PBj1.9 proviral clone. Sequences 
from SIVSM were shown in white, while the black area represented the fragment from 
HIV-1 that was inserted into the corresponding region of the SIVSM proviral clone. 
NL43 (SIV-Vif-Env ΔVpx) was the same chimera in which the expression of Vpx was 
eliminated. Vpx was deleted by mutating the start codon of Vpx and introducing an early 
stop codon. All the mutations introduced were silent mutations for vif gene. 
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indicating that these chimeric viruses are capable of single round infection in permissive 
cells (Figure 3-11B). However, infection of macrophages by NL43 (SIV-Vif-EnvΔVpx) 
was highly inefficient compared to that by NL43 (SIV-Vif-Env), as evidenced by the 
levels of viral cDNA synthesis (Figure 3-11A), suggesting Vpx dramatically enhanced 
the infectivity of this chimera in macrophages. Therefore, chimeric NL43 (SIV-Vif-Env) 
is restricted in macrophages, indicating that the 3’ half of SIVSM may contain the target 
of the macrophage restriction.  
To confirm this, another chimera between HIV-1 and SIVSM was constructed in 
which the fragment of HIV-1 vif-vpr was replaced by SIVSM vif-vpx in the context of the 
NL43 backbone. The junctions between SIVSM and HIV-1 were located at the beginning 
of vif and the end of vpx (Figure 3-12). The infectivity of these chimeric viruses in COS 
cells and macrophages was examined. In permissive COS cells, both NL43 
(SIV-Vif-Vpx) and Vpx-deleted variant NL43 (SIV-Vif-ΔVpx) underwent comparable 
reverse transcription with similar levels of 2-LTR circle production (Figure 3-13B). 
Surprisingly, 2-LTR circle production in macrophages infected with NL43 
(SIV-Vif-ΔVpx) dramatically decreased (Figure 3-13A), indicating that this chimera is 
antagonized by the macrophage restriction. The Vpx-deleted chimeras with the HIV-1 
backbone infected macrophages although with lower efficiency, suggesting that they are 
partially restricted compared to SIVSM. These results led us to consider that HIV-1 is also  
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Figure 3-11. Vpx promotes chimeric NL43 (SIV-Vif-Env) infection in macrophages. 
(A) Susceptibility of macrophages to infection by NL43 (SIV-Vif-Env) chimera and 
Vpx-deleted variant NL43 (SIV-Vif-EnvΔVpx). Macropahges were infected and virus 
infection was gauged from the levels of viral 2-LTR cDNA at 24 and 48 h post-infection. 
(B) Susceptibility of COS cells to infection by NL43 (SIV-Vif-Env) chimera and 
Vpx-deleted variant. 
 
 67
 
 
NL43 (SIV-Vif-Vpx) 
 
 
NL43 (SIV-Vif-ΔVpx) 
 
 
HIV-1 SIV 
 
Figure 3-12. A schematic of chimeric proviral clone NL43 (SIV-Vif-Vpx) and 
Vpx-deleted variant NL43 (SIV-Vif-ΔVpx). The black area represents the fragment 
from HIV-1 and the white area represents the fragment from HIV-1. The fragment from 
vif to vpx of NL43 was precisely substituted for the same domain in the PBj1.9 proviral 
clone. NL43 (SIV-Vif-ΔVpx) was the same chimera in which the expression of Vpx was 
eliminated. Vpx was deleted by mutating the start codon of Vpx and introducing an early 
stop codon. All the mutations introduced were silent mutations for vif gene. 
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Figure 3-13. Vpx promotes NL43 (SIV-Vif-Vpx) infection in macrophages. (A) 
Differential susceptibility of macrophages to infection by NL43 (SIV-Vif-Vpx) and 
Vpx-deleted variant NL43 (SIV-Vif- ΔVpx). Macropahges were infected and virus 
infection was gauged from the levels of viral 2-LTR cDNA at 24 and 48 hours post 
infection. (B) Susceptibility of COS cells to infection by by NL43 (SIV-Vif-Vpx) and 
Vpx-deleted variant. COS cells were infected and virus infection was determined as 
described in A. 
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antagonized by the macrophage restriction that blocks SIVSM infection. 
To evaluate whether the antiviral restriction which antagonized HIV-2/SIVSM 
infection was active against HIV-1 and if Vpx indeed promoted HIV-1 infection of 
macrophages, the spreading infection of macropahges by a HIV-1 variant expressing 
Vpx was examined. A chimeric construct ADAΔVpr(PBj-Vpx) was created, within 
which the sequence of Vpr in the ADA backbone was replaced by the sequence of Vpx 
derived from SIV PBj (Figure 3-14A). Since the expression of Vpr was eliminated in 
this chimera, Vpr-deleted ADA was used as a control. Macropahges were infected with 
wild-type ADA, ADAΔVpr and ADAΔVpr(PBj-Vpx) chimera that expressed Vpx. The 
culture Supernatants were collected and HIV-1 infection was determined by reverse 
transcriptase activity in the supernatants over 31 days post-infection. The infectivity of 
ADAΔVpr was lower than that of wild-type ADA in macrophages (Figure 3-14B). 
However, the infectivity of ADAΔVpr was profoundly enhanced compared to that of 
ADAΔVpr (Figure 3-14B), indicating that the expression of Vpx promoted HIV-1 
infection in macrophages. Therefore, the antiviral restriction that antagonizes SIVSM 
infection of macrophages is active against HIV-1. 
3.6 Vpx Counters the Restriction and Promotes HIV-1 infection in trans 
Vpx and Vpr are virion proteins and would thus be predicted to exert their function 
in the target cell shortly after  infection.  Therefore,   I next  examined  whether  the  Vpx  
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Figure 3-14. Vpx enhances HIV-1 spreading infection in macrophages. (A) 
Construction of ADAΔVpr(PBj-Vpx). A schematic of wild-type ADA and chimeric ADA 
which expresses SIVSM Vpx. Vpx sequence was derived from SIV PBj and was inserted 
into ADA backbone in place of Vpr. (B) Spreading infection of macrophages by 
wild-type ADA, ADAΔVpr or ADAΔVpr((PBj-Vpx). Macrophages were infected with 
RT unites (cpm) of ADA, ADAΔVpr or ADAΔVpr((PBj-Vpx). Culture supernatants 
were collected and RT activity (106 cpm/ml) was measured at 3 day intervals 
post-infection. 
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protein, when packaged in trans within HIV-1 virions, enhanced virus infectivity for 
primary macrophages. 
HIV-1 Vpr and SIVSM Vpx proteins were packaged into wild-type or Vpr-deleted 
HIV-1 viruses by cotransfection. The infectivity of those viruses for COS cells and 
macrophages was then determined from levels of viral cDNA (2-LTR circles) at 24 and 
48 hours post-infection. While Vpx had no significant effect on the infectivity of 
wild-type HIV-1, the infectivity of HIV-1ΔVpr for macrophages was profoundly 
enhanced by Vpx but not by HIV-1 Vpr (Figure 3-15, lower panel). The infectivity 
enhancement was also apparent in macrophages infected with an HIV-1 variant 
expressing GFP (Figure 3-16). Thus, while HIV-1 was infectious for macrophages, its 
ability to infect these cells was markedly enhanced in the presence of Vpx. Vpx had no 
effect on the infectivity of wild-type or ΔVpr HIV-1 for COS cells (Figure 3-15, upper 
panel). 
In the above experiments, VSV-G pseudotyped HIV-1 was used. To further confirm 
that Vpx promotes HIV-1 infection in trans, I used a non-pseudotyped HIV-1 virus 
NA20 B59/NL43, which is a macrophage tropic NL43 variant. The infectivity of NA20 
B59/NL43ΔVpr for macrophages was remarkably enhanced by packaging of SIV Vpx 
(Figure 3-17).  
Collectively, these results support our hypothesis that although HIV-1 is infectious  
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Figure 3-15. HIV-1 is sensitive to the macrophage restriction and SIV Vpx but not 
HIV-1 Vpr antagonizes the restriction. HIV-1 Vpr and SIV Vpx proteins were 
packaged in HIV-1WT or HIV-1ΔVpr viruses by cotransfection. For controls, viruses were 
cotransfected with an empty vector. The infectivity of those viruses for COS-1 cells 
(upper panel) and macrophages (lower panel) was then determined from levels of viral 
cDNA (2-LTR circles) at 24 and 48 hours post-infection. 
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Figure 3-16. Vpx enhances transduction of macrophages by GFP-expressing HIV-1. 
Infection of macrophages with GFP-expressing HIV-1ΔVpr variants in which Vpx was 
(+) or was not (–) packaged. GFP positive macrophages (representative fields) were 
visualized 48 h post-infection. 
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Figure 3-17. SIVSM Vpx promotes NA20 B59/NL43ΔVpr infection in macrophages. 
Macrophages were infected with a non-pseudotyped NL43 variant NA20 B59/NL43 (R5 
tropic) that had or had not packaged Vpx. Virus infection was  gauged from the levels 
of viral 2-LTR cDNA 24 and 48hours post inoculation. 
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for macrophages, HIV-1 is partially restricted by the same restriction factor that blocks 
SIVSMΔVpx, at the level of reverse transcription. The ability of HIV-1 to infect 
macrophages is remarkably enhanced in the presence of Vpx. However, HIV-1 Vpr is 
not able to overcome the restriction 
3.7 Vpx Renders Macrophages Permissive to MLV Infection 
A fundamental characteristic that distinguishes lentiviruses from simple 
gammaretroviruses is their capacity to infect nondividing cells (153, 154). Primate 
lentiviruses are able to transduce nondividing cells, and this underscores their ability to 
transduce terminally differentiated nondividing cells, including macrophages, microglia, 
and dendritic cells, both in vitro and in vivo (17, 155, 156). In contrast, gamma- 
retroviruses such as murine leukemia virus (MLV) transduce cells in mitosis and 
nondividing cells (in G1/S/G2) are refractory to gammaretrovirus transduction 
(157–160). Previous experiments have presented evidence that macrophages harbor a 
restriction that antagonizes HIV-1 and SIV at the level of reverse transcription and that 
the Vpx protein of SIVSM specifically overcomes this restriction. I next examined 
whether neutralization of the restriction by Vpx would render macrophages permissive 
to MLV. 
Whether introduction of Vpx into macrophages by wild-type SIV infection would 
render macrophages susceptible to subsequent transduction by MLV was first examined. 
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Macrophages were initially infected with SIVWT or SIVΔVpx and subsequently infected 
by MLV. MLV late cDNA copies (Figure 3-18A, upper panel) and 2-LTR circles 
(Figure 3-18A, lower panel) were determined 24 and 48 hours after MLV infection. The 
primary block to transduction of macrophages by MLV appeared to be at the level of 
reverse transcription (Figure 3-18A). Pre-infection of macrophages with a SIVWT but not 
a Vpx-deleted SIV (SIVΔVpx) resulted in an increased ability of MLV to transduce 
macrophages, as evidenced by MLV cDNA synthesis (Figure 3-18A) and expression of 
GFP from the MLV genome (Figure 3-18B). Therefore, the restriction that antagonizes 
lentivirus infection of macrophages also prevents infection of macrophages by MLV and 
Vpx delivered in trans permits transduction of macrophages by MLV.  
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Figure 3-18. Vpx permits transduction of macrophages by MLV in trans (A) Vpx 
delivered to macrophages by wild-type SIV (SIVWT) infection removes the block to 
synthesis of MLV cDNA in macrophages. Macrophages were initially infected with 
SIVWT or SIVΔVpx and subsequently infected by MLV-GFP after 4 hours. 
Macrophages infected with MLV without pre-infection were used as control (no Pre). 
Synthesis of MLV late cDNAs (upper panel) and 2-LTR circles (lower panel) was 
assessed 24 and 48 hours after MLV infection. (B) A representative field of 
macrophages transduced by MLV-GFP in an independent experiment. 
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CHAPTER IV                               
Proteasome/Ubiquitylation Pathway and DDB1 Interaction are 
Required for the Ability of Vpx to Counteract the Restriction 
4.1 Chapter Summary 
A possible role for the proteasome/ubiquitin system in the ability of Vpx to 
neutralize the unknown restriction was evaluated. Vpx was ubiquitylated by 
over-expressed Histidine-ubiquitin in 293 T cells, as well as by endogenous ubiquitin. 
The extent of ubiquitylation was reduced in a Vpx mutant (VpxM4) lacking all four 
lysine ubiquitylation sites. VpxM4, although packaged within HIV-1 particles, was 
defective in enhancing HIV-1 infection of macrophages. This suggestes the ability of 
Vpx to enhance HIV-1 infectivity requires its ubiquitylation. Furthermore, Vpx failed to 
enhance the permissiveness of macrophages to HIV-1 or MLV infection when 
proteasome function was disrupted by a proteasome inhibitor. This indicates that a 
functional proteasome system was necessary for the biological activity of Vpx. 
This chapter also provides evidence that a cellular binding partner for Vpr, DDB1, 
is required for the ability of Vpx to counteract the restriction. In 293T cells, endogenous 
DDB1 associated with a wild-type SIV Vpx protein but not with VpxM4, which suggests 
that Vpx ubiquitylation is required for DDB1 interaction. This may explain why 
ubiquitylation sites are important for Vpx function. Furthermore, fusion of DDB1 to SIV 
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Vpr partially restored the ability of Vpx-deleted SIV to infect macrophages. 
Vpx failed to enhance lentiviral infection in macrophages in the presence of HIV-1 
Vpr, suggesting that HIV-1 Vpr impaired the ability of Vpx to overcome the restriction. 
Vpx was packaged into wild-type HIV-1 as well as Vpr-deleted HIV-1 virions. Therefore, 
HIV-1 Vpr did not compete with SIV Vpx for virion packaging. Infection of 
macrophages by SIV harboring a wild-type Vpx gene alleviated the block to subsequent 
infection by wild-type or ΔVpr HIV-1, suggesting that HIV-1 Vpr competed with SIV 
Vpx in target cells, possibly for restriction binding. To determine if Vpr from 
lab-adapted HIV-1 lost its ability to overcome the restriction due to mutations happened 
during propagation in vitro, I examined if primary Vpr alleles derived from AIDS 
patients were able to promote HIV-1 infection. All the tested primary HIV-1 Vpr alleles 
failed to enhance HIV-1 infection. This confirmed that HIV-1 Vpr does not overcome the 
putative restriction. 
In addition, I examined the amount of Vpx needed to rescue SIVΔVpx infection in 
macrophages. The ability of trans-packaged Vpx to counteract a macrophage restriction 
is dose-dependent, and only a small amount of Vpx packaged in trans is sufficient to 
overcome the restriction in macrophages. 
4.2 Vpx Activity Requires Ubiquitylation and Functional Proteasome 
Primate lentiviruses have evolved the accessory protein Vif to counteract the 
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antiviral activity of cellular APOBEC 3 cytidine deaminases (30). Vif achieves this by 
promoting ubiquitylation and proteasomal degradation of APOBEC3 proteins (161, 162). 
Therefore Vpx possibly antagonizes the macrophage restriction through a similar 
mechanism. 
Vpx is ubiquitylated 
To evaluate a possible role for the ubiquitin-proteasome system in the activity of 
Vpx, whether Vpx itself was ubiquitylated was first examined. A Vpx mutant (VpxM4) 
containing lysine (K) to arginine (R) substitutions at all four lysine residues was 
constructed (Figure 4-1A). HA-tagged Vpx and VpxM4 were co-expressed in 293T cells 
with 6-Histidine-myc-tagged ubiquitin. Mono and poly ubiquitylated Vpx proteins were 
purified on nickel beads and western blotted. Immunoblotting with an HA antibody 
revealed the presence of mono and poly ubiquitylated forms of Vpx (Ub-Vpx, Figure 
4-1B, left panel). It was also examined whether Vpx was ubiquitylated by endogenous 
ubiquitin (as opposed to over expressed and tagged ubiquitin). HA-tagged Vpx was 
expressed in 293 T cells and cell lysates were directly Western blotted and probed with 
an HA antibody. This revealed the presence of higher molecular weight ubiquitylated 
forms of Vpx (Figure 4-1B, right panel). The extent of Vpx ubiquitylation was reduced 
in VpxM4 (Figure 4-1B, left panel). Despite mutagenesis of all four lysines in Vpx, 
polyubiquitylated  forms  of  the  protein  were  still  evident  (compare  GFP  signal with  
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Figure 4-1. Identification of ubiquitylated residues in Vpx. (A) The positions of the 
Lysine (K) to Arginine (R) mutations in VpxM4 mutant. (B) Wild-type and lysine mutant 
VpxM4 (HA tag) were expressed in 293T cells expressing Histidine-tagged ubiquitin. 
Ubiquitylated Vpx proteins (Ub-Vpx) were purified on nickel beads. Immunoblotting 
with an HA antibody revealed the presence of mono and poly ubiquitylated forms of 
Vpx (left panel). Vpx was also ubiquitylated by endogenous ubiquitin. HA-tagged Vpx 
was expressed in 293T cells and cell lysates were directly blotted with anti-HA. The 
presence of higher molecular weight Ub-Vpx was revealed (right panel). 
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VpxM4 signal, Figure 4-1B, left panel). This suggested an involvement of both lysine and 
nonlysine residues in Vpx ubiquitylation (163, 164). 
VpxM4 does not enhance HIV-1 infection in macrophages. 
I first examined if VpxM4 mutant was able to be packaged into HIV-1 virions. 
VpxM4 was packaged within HIV-1 particles at levels indistinguishable from wild-type 
Vpx (Figure 4-2). The packaging of the VpxM4 in viral particles suggests, at the very 
least, that this mutant is competent for binding to the p6 domain of the viral Gag 
polyprotein through which packaging of Vpr and Vpx protein is mediated (112, 113).  
I next evaluated whether the ability of Vpx to enhance HIV-1 infectivity depended 
upon its ubiquitylation. Wild-type SIVSM Vpx, VpxM4 or wild-type HIV-1 Vpr were 
packaged within HIV-1ΔVpr virions by cotransfection. Empty vector was cotransfected 
with HIV-1 proviral clone as a control. Single cycle infection of macrophages was 
evaluated from synthesis of 2-LTR cDNAs. Package of Vpx dramatically promoted 
HIV-1 infection of macrophages (Figure 4-3). VpxM4 did not enhance HIV-1 infectivity 
when packaged within HIV-1ΔVpr virions (Figure 4-3), indicating the ability of Vpx to 
enhance the infectivity of HIV-1ΔVpr was compromised by the M4 mutation. To 
conclude, a Vpx mutant lacking lysine ubiquitylation sites failed to enhance macrophage 
infection by HIV-1. Therefore, the ability of Vpx to enhance HIV-1 infectivity for 
macrophages requires its ubiquitylation. 
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Figure 4-2. Packaging of Vpx proteins in wild-type and Vpr-deleted HIV-1. HA 
tagged wild-type Vpx or VpxM4 proteins were packaged within NL43WT or NL43ΔVpr by 
cotransfection. The virions were collected and pelleted with 20% sucrose cushion. 
Virion lysates are subject to SDS-PAGE and blotted with anti-p24 (left panel) or 
anti-HA (right panel). 
 
 86
 
 
Figure 4-3. Ubiquitylation is required by Vpx for enhancement of HIV-1 infectivity 
in macrophages. Wild-type HIV-1 Vpr, SIV Vpx or lysine mutant Vpx (VpxM4) 
proteins were packaged in HIV-1ΔVpr and infectivity of those viruses was assessed in 
macrophages. Viral cDNA synthesis was evaluated 24 and 48 h post-infection. 
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A functional proteasome is necessary for the ability of Vpx to enhance HIV-1 and 
MLV infection 
Whether the ability of Vpx to regulate HIV-1 and MLV infection of macrophages 
required proteasome function was then examined. Macrophages were treated with two 
different proteasome inhibitors and then infected with HIV-1ΔVpr variants that had 
packaged wild-type Vpx or VpxM4. 2-LTR cDNA was quantitated 24 hours after 
infection. ALLN and proteasome inhibitor 1 (Prot.1) markedly impaired infection of 
macrophages by HIV-1ΔVpr containing wild-type Vpx (Figure 4-4A). In contrast, 
macrophage infection by HIV-1ΔVpr which does not contain wild-type Vpx was not 
dramatically compromised by the proteasome inhibitors (Figure 4-4A). Since 
proteasome disruption only impacted macrophage infection by HIV-1ΔVpr containing 
Vpx, this argued that proteasome inhibition specifically impaired Vpx function rather 
than impacting virus infection through off-target effects.  
I also examined if the ability of Vpx to render macrophages permissive to MLV 
infection required a functional proteasome. Macrophages were treated with the 
proteasome inhibitor ALLN, or DMSO as control. The cells were then infected with 
wild-type or Vpx-deleted SIV, and subsequently infected with MLV after 6 hours. MLV 
cDNA production was quantitated by real-time PCR 24 and 48 hours post-infection. Vpx 
delivered   to   macrophages   by   wild-type   SIV   pre-infection  rendered  macrophages  
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Figure 4-4. The ability of Vpx to enhance permissivity of macrophages to HIV-1 
and MLV infection requires a functional proteasome. Effects of proteasome 
inhibitors on HIV and MLV infection of macrophages are indicated. (A) Macrophages 
were treated with the proteasome inhibitors ALLN or proteasome inhibitor 1 (Prot. 1) or 
with DMSO as a control. Those cells were then infected with HIV-1ΔVpr variants which 
had packaged wild-type or lysine mutant Vpx proteins. The level of HIV-1 infection 
(2-LTR cDNA) was determined 24 hours post-infection by PCR. (B) Macrophages were 
treated with the proteasome inhibitor ALLN or with DMSO as a control. Those cells 
were initially infected with wild-type or ΔVpx SIV, and subsequently infected by MLV. 
The level of MLV infection (late cDNA) was determined 24 and 48 hours post-infection. 
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permissive to MLV (Figure 4-4B). However, Vpx was not able to rescue MLV infection 
of macrophages in cells that were treated with a proteasome inhibitor (Figure 4-4B). 
Vpx failed to enhance permissiveness of macrophages to HIV-1 or MLV infection in 
macrophages in which proteasome function was disrupted by proteasome inhibitors. 
Therefore, the ability of Vpx to enhance HIV-1 infectivity or to rescue MLV infection 
required proteasome function. 
Collectively, these experiments indicate the presence of a potent antiviral 
restriction in macrophages that is counteracted by the Vpx protein and that the 
proteasome/ubiquitin system is required for the ability of Vpx to counteract this 
restriction. 
4.3 Vpx Function Requires DDB1 
Recent studies have demonstrated that the ability of HIV-1 Vpr to induce cell cycle 
arrest requires the E3 ubiquitin ligase complex scaffolding factor, damaged DNA 
binding protein 1 (DDB1) (118–119120121 22). Therefore, whether the ability of Vpx to 
counteract the macrophage restriction to SIV and HIV-1 infection was DDB1-dependent 
was examined. 
First experiment investigated whether DDB1 is required for Vpx ubiquitylation or 
Vpx ubiquitylation is required for DDB1 interaction. In 293T cells, endogenous DDB1 
associated with a wild-type SIV Vpx protein but  not  with  VpxM4 (Figure 4-5A). A  
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Figure 4-5. Vpx ubiquitylation is required for Vpx interaction with DDB1. (A) 
Association of SIV Vpx with endogenous DDB1. Association of DDB1 with wild-type 
Vpx (VpxWT) and non-ubiquitylated Vpx (VpxM4) was evaluated in 293T cells 
expressing FLAG-tagged Vpx or IRES-GFP as a control. FLAG immunoprecipitates 
were immunoblotted with DDB1 or FLAG antibodies (upper panels). Levels of 
endogenous DDB1 and expressed Vpx in cell lysates were confirmed by Western 
blotting with a DDB1 antibody and with a FLAG antibodie respectively. (lower panels) 
(B) Impact of DDB1 silencing on Vpx ubiquitylation. 293T cells were cotransfected 
with DDB1 or scrambled siRNAs and with Histidine-ubiquitin and HA-Vpx or 
IRES-GFP expression plasmids as outlined in Figure 4-1. Ubiquitin-conjugated proteins 
were nickel purified and immunoblotted for HA-Vpx (upper panels). Cell lysates were 
directly blotted for Vpx and DDB1 proteins (lower two panels).
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specific association of SIV Vpx with DDB1 was apparent in coimmunoprecipitation 
experiments with FLAG-tagged Vpx protein (Figure 4-5A). Although ubiquitylation was 
necessary for the ability of Vpx to counteract the restriction to HIV-1 and SIV infection 
of macrophages, DDB1 protein was not required for Vpx ubiquitylation  (Figure 4-5B). 
Mono and poly ubiquitylated forms of Vpx were evident and apparently increased in 
cells in which DDB1 expression was reduced by RNA interference (Figure 4-5B).  
Whether DDB1 was required for the ability of Vpx to counteract the restriction to 
HIV-1 infection was next examined. Since Vpx, when packaged in HIV-1 virions, 
enhanced macrophage infection, a transpackage strategy was used to examine whether 
Vpx enhanced HIV-1 infection in DDB1 depleted macrophages. While packaging of 
Vpx in HIV-1 particles markedly increased infectivity for macrophages transfected with 
a scrambled siRNA (Figure 4-6A), silencing of DDB1 in macrophages significantly 
reduced the ability of Vpx to enhance HIV-1 infection (Figure 4-6A). However, HIV-1 
Vpr did not antagonize a macrophage restriction. The activity of the restriction in HIV-1 
was only revealed by the ability of Vpx to enhance HIV-1 infection of macrophages. In 
agreement with this, DDB1 silencing had no significant effect on the infectivity of 
HIV-1 which had not packaged Vpx (Figure 4-6A). Therefore, DDB1 appears to be a 
specific Vpx cofactor in primary macrophages. 
Since  SIV  Vpx  but not SIV Vpr was essential  for  macrophage  infection  (Figure  
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Figure 4-6. DDB1 is required for the ability of Vpx to counteract the restriction to 
macrophage infection by HIV-1 and SIV. (A) SIV Vpx (or GFP as a control) was 
packaged into HIV-1ΔVpr virions by co-transfection. Infectivity of those viruses for 
DDB1-depleted macrophages (DDB1 siRNA) or control macrophages (ScrI siRNA) 
were evaluated from levels of viral cDNA 24 h later (+, p>0.2; *, p<0.002). (B) DDB1 
packaging partially substitutes for Vpx. A Vpx/Vpr deletion mutant of SIV (SIVΔXR) 
was co-transfected with vectors expressing SIV Vpr, SIV Vpx, DDB1 or a Vpr-DDB1 
fusion. Infectivity of the resulting viruses for macrophages was evaluated from levels of 
SIV cDNA at 24 and 48 hours post-infection (*, p<0.005). 
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3-1A), I examined whether fusion of DDB1 to SIV Vpr was sufficient to allow SIV Vpr 
to counteract the macrophage restriction. Packaging of Vpr alone into a Vpr and 
Vpx-deleted SIV (SIVΔXR) did not permit macrophage infection. In contrast, there was a 
partial and significant restoration of infectivity when a Vpr-DDB1 fusion was packaged 
relative to infectivity of virions in which the DDB1 protein was not packaged (Figure 
4-6B). Collectively, these results suggest that DDB1 is required for the ability of Vpx to 
antagonize a restriction to infect macrophages by HIV and SIV, but that DDB1 is not 
required for Vpx ubiquitylation. 
4.4 HIV-1 Vpr Impairs the Ability of Vpx to Neutralize the Macrophage 
Restriction 
Previous experiments demonstrated that Vpx had the ability to compliment 
HIV-1ΔVpr but not wild-type HIV-1 (Figure 3-15 and Figure 3-17). Therefore, one 
possibility is that the ability of Vpx to promote HIV-1 infection is compromised by the 
presence of HIV-1 Vpr. To assess this hypothesis I packaged SIVSM Vpx or HIV-1 Vpr 
into a Vpx-expressing HIV-1 variant NL43 (SIV-Vif-Vpx), or NL43 (SIV-Vif-ΔVpx) 
that does not express Vpx. The infectivity of NL43 (SIV-Vif-Vpx) was dramatically 
higher than that of NL43 (SIV-Vif-ΔVpx) in macrophages, as evidenced by viral 2-LTR 
production (Figure 4-7). However, packaging of HIV-1 Vpr into NL43 (SIV-Vif-Vpx) 
virions profoundly decreased virus infection of macrophages, to a level similar to NL43 
(SIV-Vif-ΔVpx) (Figure 4-7). This  confirmed  that  the packaged HIV-1 Vpr protein  
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Figure 4-7. HIV Vpr inhibits the ability of SIVSM Vpx to antagonize the 
macrophage restriction. Macrophages were infected with NL43 (SIV-Vif-Vpx) which 
had packaged SIVSM Vpx or HIV-1 Vpr proteins. The infectivity of those viruses was 
gauged from the levels of HIV-1 2-LTR circle 24 and 48 hours post infection. 
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inhibited the ability of Vpx to neutralize the macrophage restriction. 
A possible explanation is that Vpx and HIV-1 Vpr proteins compete for packaging 
within HIV-1 virions. An alternative possibility is that these proteins do not compete for 
packaging into virions but compete for interaction with the restriction after infection has 
occurred. Western blotting analysis revealed that Vpx proteins were packaged into 
wild-type and Vpr-deleted HIV-1 virions (Figure 4-2). This suggested that HIV-1 Vpr 
competed with Vpx in the target cell following infection and this competition precluded 
the ability of Vpx to neutralize the restriction. A prediction of this is that delivery of Vpx 
to this target cell prior to HIV-1 infection should be sufficient to inactivate the 
restriction and subsequently enhance macrophage infection by both wild-type and 
Vpr-deleted HIV-1. To evaluate this, I bypassed the requirement for Vpx packaging by 
directly introducing Vpx into the target cell by SIVWT infection. The susceptibility of 
those cells to infection by wild-type or Vpr-deleted HIV-1 variants was then examined. 
The infectivity of both wild-type and Vpr-deleted HIV-1 variants for macrophages was 
enhanced when Vpx was first introduced into the cell by SIVWT infection (Figure 4-8). 
In contrast, prior infection with a SIVΔVpx variant did not enhance subsequent HIV-1 
infection of macrophages (Figure 4-8). Therefore, in the absence of competition by 
packaged Vpr, Vpx greatly enhanced wild-type HIV-1 infectivity for macrophages.  
In summary, HIV-1 Vpr does not  abrogate Vpx packaging  into HIV-1  virions.  
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Figure 4-8. Vpx delivered to macrophages by SIVWT infection enhances the 
permissivity to HIV-1WT and HIV-1ΔVpr infection. Macrophages were first infected 
(1º infection) with wild-type or ΔVpx SIV variants, left uninfected (none) or treated 
with AZT. After 8 h, these cells were super-infected (2º infection) with WT or ΔVpr 
HIV-1 variants and HIV-1 infection (2-LTR cDNA synthesis) was determined 24 and 48 
h later. 
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Instead, HIV-1 Vpr interferes with Vpx function in target cells, possibly by competing 
for interaction with the restriction factor. Without competition from HIV-1 Vpr, SIVSM 
Vpx delivered into macrophages by SIV pre-infection antagonizes the restriction and 
enhances wild-type HIV-1 infection. 
4.5 Primary HIV-1 Vpr Alleles Fail to Overcome the Macrophage Restriction 
Initial experiments demonstrated that both HIV-1 and SIVSM were antagonized by 
a macrophage restriction factor. Although HIV-1 was only partially restricted in 
macrophages and infected macrophages to a moderate level, the introduction of Vpx 
dramatically enhanced its infectivity. One possibility is that HIV-1 Vpr antagonizes the 
macrophage restriction but the ability of Vpr to overcome the restriction is lost during 
viral expansion in lymphocyte culture. HIV-1 Vpr induces cell cycle arrest; therefore, it 
is possible that during viral propagation in vitro, viruses with mutations in vpr that are 
less efficient in inducing G2 cell cycle arrest are selected. As a result, Vpr from 
lab-adapted viruses may lose the ability to counteract the restriction factor.  
To test this hypothesis, I examined if primary Vpr alleles derived from AIDS 
patients were able to neutralize the macrophage restriction and promote HIV-1 infection. 
PBMCs were obtained from AIDS patients with high viral load. Primary Vpr sequences 
were amplified from total cDNA and then cloned into a p-IRES-EGFP expression vector. 
Primary Vpr proteins were packaged into Vpr-deleted HIV-1 virions by cotransfection. 
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While HIV-1 containing wild-type NL43 Vpr moderately infected macrophages, 
encapsidation of SIVSM Vpx enhanced HIV-1 infectivity in macrophages dramatically 
(Figure 4-9). However, none of the primary Vpr alleles obtained from clinical samples 
enhanced HIV-1 transduction in macrophages (Figure 4-9), suggesting that the primary 
Vpr alleles do not neutralize the macrophage restriction. 
4.6 The Ability of Vpx to Neutralize the Restriction is Dose Dependent 
Previous experiments have demonstrated that Vpx delivered in trans by virus 
particles enhances the permissivity of macrophages to SIVSM and HIV-1 infection. I next 
titered the amount of Vpx needed to rescue SIVΔVpx infection in macrophages and 
whether the ability of packaged Vpx to counteract the macrophage restriction was 
dose-dependent. Since primary macrophages cannot be transfected with Vpx expression 
plasmids and expression of Vpx following infection of macrophages with viruses 
containing packaged Vpx has not been detectable with available Vpx antibodies, I 
conducted an experiment in which different amounts of Vpx were packaged into SIVSM 
virions. 
A Vpx-deleted SIV (SIVΔVpx) variant expressing GFP was used for this 
experiment. Increasing amount of Vpx was packaged into SIVΔVpx by cotransfection. 
Wild-type SIV was used as a control. The levels of packaged Vpx in the purified virions 
were determined by western blotting with a Vpx antibody and were normalized with p27  
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Figure 4-9. Primary HIV-1 Vpr alleles fail to overcome the macrophage restriction. 
Primary Vpr alleles were derived from AIDS patient plasma. NL43 Vpr and primary Vpr 
proteins were packaged into Vpr deleted HIV-1 (NL43ΔVpr) virions by cotransfection. 
The infectivity of those viruses for macrophages was then determined from levels of 
2-LTR cDNA 24 and 48 hours post-infection. 
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level. With increasing amount of a co-transfected Vpx-expressing plasmid, an increasing 
amount of Vpx in viral particles was observed (Figure 4-10A). When 0.5µg 
Vpx-expressing plasmid was cotransfected with 9µg SIVΔVpx proviral DNA, the 
amount of Vpx packaged into SIVΔVpx virions reached a level similar to that of 
wild-type SIV (Figure 4-10A). 
The infectivity of these viruses in primary macrophages was determined from the 
levels of SIV 2-LTR circle or late cDNA 24 and 48 hours post-infection. The percentage 
of infected (GFP+) cells was determined by FACS. An increasing level of 2-LTR 
production was observed with increasing amount of packaged Vpx (Figure 4-10B). The 
percentage of GFP+ post infection was also proportional to the amount of Vpx packaged 
into particles (Figure 4-10C). This suggests that the ability of packaged Vpx to 
counteract a macrophage restriction is dose-dependent. It was also observed that even a 
small amount of trans-packaged Vpx can counter the restriction present in macrophages 
(Figure 4-10). Vpx is packaged in molar amounts equivalent to Gag proteins (165). 
Assuming ~2000 Gag molecules per virion (166), and assuming uniform Vpx:Gag 
stoichiometry in each viral particle, Vpx packaged at ~10% of wild-type levels still 
rescued a ΔVpx virus (Figure 4-10), suggesting that as few as 200 Vpx molecules/virion 
can counteract the restriction. 
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Figure 4-10. Dose-dependent ability of packaged Vpx to counteract a macrophage 
restriction. Pseudotyped SIVΔVpx (X2) was produced in 293T cells by cotransfecting 
SIVΔVpx proviral DNA with pVSV-G and increasing amount of a Vpx expression 
vector. (A) The amount of packaged Vpx in the purified virions was determined by 
western blotting with a Vpx antibody and normalization with p27 by densitometry. The 
integrated density was measured by Scion Image software. (B) The infectivity of these 
viruses in primary macrophages was determined from quantitation of SIV 2-LTR cDNA 
24 and 48 h post-infection. PBjWT was used as positive control for this experiment. (C) 
Virus transduction was determined from percentage of GFP+ cells 48 and 72 h 
post-infection by FACS. 
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CHAPTER V                                   
Vpx Renders Primary Monocytes Permissive to HIV-1 Transduction 
5.1 Chapter Summary 
Quiescent monocytes are highly refractory to HIV-1 and the infection is blocked at 
an early post-entry step. Susceptibility to infection occurs only upon differentiation of 
monocytes to macrophages (126, 134, 135). A heterokaryon experiment was used to 
examine if the resistance of monocytes to infection in vitro was due to the absence of a 
positive factor or the presence of a restriction factor. The fusion of nonpermissive 
monocytes with permissive HeLa cells did not remove the block to HIV-1 infection, 
suggesting the presence of a restriction factor in monocytes. 
The Vpx protein of SIVSM counteracts a macrophage restriction and enhances 
HIV-1 infection in macrophages. I therefore examined whether the same restriction is 
operative in monocytes. Packaging of Vpx within HIV-1 virions conferred the ability to 
transduce quiescent monocytes, as evidenced by increased cDNA production and GFP 
expression. Additionally, Vpx introduced by pre-infecting monocytes with wild-type 
SIV also removed the block to infection by HIV-1. 
To confirm that Vpx rendered undifferentiated monocytes permissive to HIV-1 
without inducing monocyte differentiation into macrophages, the expression of CD71 
post-infection was examined. Infection of monocytes by HIV-1 either with or without 
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Vpx did not have an effect on temporal expression of CD71. I also examined whether 
HIV-1 transduction was restricted to a small percentage of differentiated CD71+ 
macrophages in the culture. As the frequency of GFP+ cells increased, there was no 
apparent bias to an increased frequency of CD71+/GFP+ cells, confirming that Vpx 
directly rendered undifferentiated monocytes permissive to HIV-1 transduction. 
Previous studies have suggested that an enzymatically active, low-molecular -mass 
(LMM) APOBEC3G complex contributes to the resistance of monocytes to lentiviral 
infection. To determine whether Vpx rendered monocytes permissive to HIV-1 by 
inducing a shift of APOBEC3G into an enzymatically inactive HMM complex, I 
examined APOBEC3G complexes in monocytes infected with wild-type or Vpx deleted 
SIV. The majority of APOBEC3G in quiescent monocytes was present as a LMM form. 
Introduction of Vpx into the monocytes did not significantly shift APOBEC3G into a 
HMM APOBEC3G complex. This suggested that the impact of Vpx on monocyte 
permissivity to HIV-1 infection was not due to changes in APOBEC3G distribution. 
In conclusion, our studies indicate that the ability of primate lentiviruses to infect 
quiescent monocytes is governed by a cellular restriction. Vpx is necessary and 
sufficient to remove this restriction and permit the transduction of quiescent monocytes 
by HIV-1. 
5.2 The Resistance of Quiescent Monocytes to Lentivirus Transduction is 
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Governed by a Restriction 
The first experiment investigated whether the fusion of HeLa cells with monocytes 
would result in heterokaryons that are permissive to HIV-1 infection. To generate HeLa- 
monocyte heterokaryons, the fusogenic properties of Sendai Virus (hemmaglutinating 
virus of Japan; HVJ) envelope proteins were exploited. The susceptibility of those 
heterokaryons to HIV-1 infection was then examined. HIV-1 infection was determined 
by luciferase activity expressed from the HIV-1 genome (values were expressed as 
percentages of those obtained with HeLa cells). As with unfused monocytes, 
HeLa-monocyte heterokaryons were highly refractory to transduction by HIV-1 (Figure 
5-1A), suggesting the presence of a negative factor in nonpermissive monocytes.  
The ability of Vpx to overcome the block to HIV-1 infection of HeLa-monocyte 
heterokaryons was next examined. Heterokaryons between monocytes and between 
HeLa cells that expressed the Vpx protein was constructed (Figure 5-1B). In this case, 
the permissivity of HeLa-monocyte heterokaryons to HIV-1 transduction was increased 
by Vpx whereas HeLa-monocyte heterokaryons not expressing Vpx remained refractory 
to HIV-1 transduction (Figure 5-1B). Since Vpx does not increase the efficiency of 
HIV-1 infection in HeLa cells, this result was not due to infection of unfused HeLa cells. 
Therefore, the heterokaryons formed between nonpermissive monocytes and permissive 
HeLa cells are  nonpermissive, due to the presence of a dominant restriction,  and that  
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Figure 5-1. Transduction of primary monocytes by HIV-1 is blocked by a 
restriction. Heterokaryons were formed between primary monocytes and HeLa cells 
using HVJ envelope fusion kit. (A) Hela-monocyte heterokaryons are highly refractory 
to transduction by HIV-1. FACS analysis of HeLa-monocyte heterokaryons is shown on 
the left panels. HeLa cells expressed GFP and macrophages were stained with an 
APC-conjugated anti-CD14. Double-stained cells were sorted as indicated by the gate. 
HIV-1 infection was gauged from luciferase activity (right panels). Values were 
expressed relative to those obtained for HeLa cells. (B) Vpx renders HeLa-monocyte 
heterokaryons permissive to HIV-1 infection. Heterokaryons were formed between 
primary monocytes and HeLa cells expressing Vpx as described in A). Susceptibility of 
HeLa-monocyte heterokaryons to HIV-1 infection was examined after expression of 
Vpx in HeLa cells. FACS analysis of HeLa-Vpx-monocyte heterokaryons is shown on 
the left panels. Double-stained cells were sorted as indicated by the gate. Infection of 
monocytes and infection of HeLa-monocyte heterokaryons with and without Vpx was 
gauged by luciferase activity (right panels). 
 109
Vpx was sufficient to render HeLa-monocyte heterokaryons permissive to HIV-1 
infection.  
5.3 Vpx Counteracts a Monocyte Restriction to HIV-1 Infection in trans 
During HIV-1 infection of macrophages, the restriction is neutralized by Vpx 
proteins that are encapsidated within the virus particle. Therefore, I examined whether 
packaging of Vpx within virions would be sufficient to confer upon HIV-1 the ability to 
transduce quiescent monocytes. Vpx proteins were packaged into HIV-1 virions by 
cotransfecting LAIΔVpr-GFP proviral DNA with a Vpx expression plasmid. HIV-1 
containing Vpr or empty vector was used as control. Fresh monocytes were infected 
with different viruses and viral 2-LTR and late product cDNA synthesis was determined 
24, 48 and 72 hours post-infection. Transduction by HIV-1 (based on GFP expression) 
was visualized 72h after monocyte infection. HIV-1 infection of quiescent monocytes 
was blocked at, or prior to, reverse transcription as evidenced by viral cDNA production 
(Figure 5-2A). The transduction efficiency was similar for HIV-1ΔVpr with or without 
Vpr packaged in trans (Figure 5-2). Packaging of Vpx within HIV-1ΔVpr virions 
markedly increased the efficiency of transduction in primary monocytes, in terms of 
viral cDNA synthesis (Figure 5-2A) and GFP expression from the HIV-1 genome 
(Figure 5-2B). Furthermore, HIV-1 cDNA that was detected in these monocytes was 
synthesized de novo and was inhibited in the presence of AZT (Figure 5-2A). These  
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Figure 5-2. HIV-1 virions encapsidating Vpx efficiently transduce primary 
monocytes. (A) Monocytes were infected with HIV-1ΔVpr-GFP variants in which Vpx 
was packaged. Levels of HIV-1 late cDNA (upper panel) and 2-LTR circle (lower panel) 
production were gauged on the indicated intervals post-infection. (B) GFP expression 
was visualized 72 hours post-infection. Representative fields of primary monocytes 
following transduction by HIV-1-GFP is shown. 
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results suggest that packaging of Vpx within HIV-1 Virions confers the ability to 
transduce quiescent monocytes. 
I next examined whether introduction of Vpx into monocytes by pre-infection 
would remove the monocyte restriction. Since monocytes were partially permissive to 
SIVWT transduction, Vpx was introduced into monocytes by SIVWT infection, and those 
monocytes were subsequently examined for permissivity to HIV-1. SIV infection 
rendered monocytes highly permissive to subsequent HIV-1 infection, as evidenced by 
an increase in HIV-1 cDNA synthesis (Figure 5-3A). In contrast, monocytes that had not 
been preinfected with SIV remained refractory to HIV-1 (Figure 5-3A). Furthermore, 
monocytes infected with SIVWT but not SIVΔVpx could be transduced by HIV-1, as 
evidenced by expression of GFP from the HIV-1 genome (Figure 5-3B). Therefore, Vpx 
introduced by SIV infection removes the block to Monocyte infection by HIV-1. 
Collectively these results indicate that Vpx is sufficient to render primary monocytes 
permissive to HIV-1 infection in trans. 
5.4 Vpx Renders Monocytes Permissive to HIV-1 Infection without Inducing 
Monocyte Differentiation 
Quiescent monocytes acquire permissivity to HIV-1 transduction once they 
differentiate into macrophages (126, 134, 135). Vpx may not permit transduction of 
undifferentiated  monocytes  by  HIV-1,  but  rather,  rapidly  induced monocyte  
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Figure 5-3. Vpx delivered to monocytes by SIVWT infection removes a block to 
subsequent infection by HIV-1. (A) Infection of monocytes by wild-type SIV removes 
a reverse transcription block to subsequent infection by HIV-1. SIVWT-infected 
monocytes were subsequently infected (6 hours later) by HIV-1. Levels of HIV-1 late 
cDNA (upper panel) and 2-LTR circle (lower panel) production were gauged on the 
indicated intervals post-infection. (B) Prior infection by SIVWT but not SIVΔVpx 
renders primary monocytes permissive to subsequent transduction by HIV-1. Monocytes 
were infected as in A and were visualized 72 hours post-infection by phase and 
fluorescence microscopy. 
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differentiation into macrophages that are permissive to HIV-1 infection. To examine the 
effect of Vpx protein on monocyte differentiation, Monocytes were infected with 
HIV-1ΔVpr with or without Vpx, and the percentage of CD14+ (monocyte/macrophage) 
or CD71+ (macrophage) cells was determined by FACS at indicated intervals 
post-infection. HIV-1 virions harboring Vpx protein efficiently transduced primary 
monocytes as evidenced by GFP expression from the HIV-1 genome (Figure 5-4A). 
CD14 expression remained constant throughout 6 days post-infection (Figure 5-4B, 
upper panel). CD71 expression increased gradually, indicating ongoing monocyte 
differentiation in culture (Figure 5-4B, lower panel). Although there were dramatic 
differences in GFP expression level between monocytes infected with HIV-1 
encapsidating Vpx and cells infected with HIV-1 not containing Vpx (Figure 5-4A), 
there were no significant differences in CD14 or CD71 expression (Figure 5-4B). In 
conclusion, infection of monocytes by HIV-1 either with or without Vpx did not have an 
effect on temporal expression of CD14 or CD71, suggesting that Vpx affected monocyte 
permissivity independent of differentiation status. 
5.5 Vpx Promotes HIV-1 Infection of Quiescent Monocytes without Preferably 
Infecting Differentiated Monocytes 
Another possibility is that HIV-1 transduction was restricted to a small percentage 
of differentiated (CD71+) macrophages in the culture.  To examine  this,  frequencies of  
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Figure 5-4. Vpx Renders Monocytes Permissive to HIV-1 Infection without 
Inducing Monocyte Differentiation. (A) HIV-1 virions encapsidating Vpx efficiently 
transduce primary monocytes. Monocytes were infected with HIV-1ΔVpr-GFP variants 
in which Vpx was or was not packaged. Levels of transduction (percentage of GFP+ 
monocytes) were determined at the indicated intervals after monocyte infection. (B) Vpx 
does not affect differentiation status of monocytes in culture. Fresh monocytes were 
infected with HIV-1ΔVpr-GFP that had or had not packaged Vpx, and the percentage of 
monocyte/macrophage (CD14+, upper panel) and differentieated monocyte (CD71+, 
lower panel) subsets was determined by FACS at the indicated intervals post-infection. 
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infected monocytes (CD71–) and macrophages (CD71+) were examined by FACS 
following infection with a GFP-expressing HIV-1 variant in which Vpx had been 
packaged. Packaging of Vpx within HIV-1 virions markedly increased their ability to 
transduce undifferentiated monocytes, as evidenced by percentage of GFP+ cells in 
CD71– subset (Figure 5-5), arguing against the possibility that HIV-1 virions containing 
Vpx selectively transduced differentiated cells. Furthermore, as the frequency of GFP+ 
cells increased, there was no apparent bias to an increased frequency of CD71+/GFP+ 
cells (Figure 5-6A). Indeed, the frequencies of infected CD71– monocytes at day 2, 3 
and 4 post-infection paralleled those for infected CD71+ cells (Figure 5-6A). In an 
independent experiment, equivalent transduction of CD71+ and CD71– by HIV-1 over 6 
days post-infection was maintained (Figure 5-6B).  
As infected monocytes do not begin to express GFP until 2-3 days in culture, viral 
cDNA synthesis in CD71– monocytes 24 and 48 hours post infection was examined, to 
determine if Vpx rendered CD71– monocytes permissive to HIV-1 at early stages of 
infection. Packaging of Vpx within HIV-1 virions markedly increased 2-LTR circle and 
late cDNA levels in CD71– cells (Figure 5-7). Collectively, these results indicate that 
Vpx directly renders undifferentiated monocytes permissive to HIV-1 transduction 
without preferentially infecting differentiated cells. 
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Figure 5-5. HIV-1 virions encapsidating Vpx efficiently transduce CD71– monocytes. 
Fresh monocytes were infected with HIV-1ΔVpr-GFP that had or had not packaged Vpx. 
The frequency of GFP-expressing cells in CD71– subset was determined by FACS at 
indicated intervals post-infection. 
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Figure 5-6. HIV-1 with encapsidated Vpx equally transduces undifferentiated 
(CD71–) and differentiated (CD71+) monocyte populations. (A) Fresh monocytes 
were infected with HIV-1ΔVpr in which Vpx had been packaged (lower three panels), 
and the frequencies of infected GFP+CD71+ macrophages and GFP+CD71– monocytes 
were determined by FACS. Upper three panels depict controls for gating. (B) The 
frequency of HIV-1 infection in CD71+ and CD71– cells at different intervals 
post-infection. 
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Figure 5-7. Vpx enhances late product and 2-LTR cDNA production in 
undifferentiated CD71– cell population. Freshly isolated monocytes were infected with 
HIV-1ΔVpr with or without Vpx. CD71– cells were sorted by FACS 24h and 48 hours 
post-infection. HIV-1 2-LTR circles (upper panel) and late cDNAs (lower panel) were 
determined by real-time PCR.. 
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5.6 Vpx Affects Monocyte Permissivity Independent of APOBEC3G 
Previous studies have demonstrated that APOBEC3G exists predominantly in a 
LMM complex in quiescent monocytes and that this complex restricts infection of 
monocytes by HIV-1. Differentiation of monocytes to macrophages redistributes 
APOBEC3G into a HMM complex and this correlates with the permissivity of macrophage 
to HIV-1 infection. (22, 137, 138). To investigate the possibility that Vpx rendered 
monocytes permissive to infection by causing a shift in APOBEC3G from LMM to 
HMM complexes, I compared the distribution of APOBEC3G in uninfected monocytes 
and in monocytes infected with wild-type SIV and SIV ΔVpx.  
Fresh monocytes were infected with wild-type SIV or SIVΔvpx, and the cells were 
collected 1 day post-infection for APOBEC3G analysis. H9 cell, fresh monocytes (d0) 
and differentiated macrophages (d10) were used as controls. As published previously 
(137), APOBEC3G was sequestered primarily in a HMM complex in H9 cells and in 
differentiated (day 10) macrophages (Figure 5-8). RNase treatment of HMM complexes 
from H9 cells led to the formation of LMM APOBEC3G complexes (Figure 5-8). In 
undifferentiated (day 0) monocytes, APOBEC3G was sequestered primarily in an LMM 
complex (Figure 5-8). Infection of monocytes by wild-type or Vpx-deleted SIV did not 
noticeably alter distribution of APOBEC3G between LMM and HMM complexes 
(Figure 5-8).  
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Figure 5-8. Vpx renders monocytes permissive to HIV-1 infection without inducing 
APOBEC3G redistribution.  Distribution of APOBEC3G between LMM and HMM 
nucleoprotein complexes in undifferentiated (d0) monocytes, differentiated (d10) 
macrophages and SIV-infected monocytes is shown. Distribution of APOBEC3G 
between H9 cell-derived HMM and LMM complexes before and after RNase treatment 
is shown for comparison. 
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CHAPTER VI                                  
Summary and Discussions 
6.1 Myeloid Cell Permissivity to Lentiviruses and Gammaretroviruses is 
Determined by a Restriction 
Our study and other studies have suggested that the accessory proteins Vpr and 
Vpx of primate lentiviruses have evolved to specifically promote infection of 
nondividing myeloid-lineage cells (33, 36–37 8, 167, 168). By generating heterokaryons 
between cells in which Vpx was dispensable for infection and primary macrophages in 
which Vpx was required for SIV infection, it was demonstrated that macrophages harbor 
a dominant restriction and that this restriction is specifically counteracted by Vpx. 
HIV-1 Vpr did not exhibit the ability to counter the macrophage restriction. For this 
reason, deletion of Vpr did not impair susceptibility of macrophages to HIV-1 infection. 
However, the fact that the restriction was active against HIV-1 was revealed by the 
demonstration that Vpx greatly increased the permissivity of macrophages to HIV-1 
infection. I also demonstrated that this restriction is an obstacle to transduction of 
terminally differentiated macrophages by the gammaretrovirus MLV. Furthermore, I 
present evidence that the ability of lentiviruses to transduce quiescent monocytes is 
regulated by this same restriction and that neutralization of the restriction in monocytes 
confers susceptibility to lentivirus infection. Previous studies have also demonstrated 
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that SIV is more efficient than HIV-1 in transducing primary monocytes and that 
deletion of Vpx prevented monocyte transduction by SIV (169). Collectively, our results 
suggest that the relative ability of lentiviruses and gammaretroviruses to transduce 
nondividing myeloid cells is governed primarily by their ability to neutralize a 
restriction that is present within these cells. 
Current models, based primarily on studies with artificially growth-arrested cell 
lines, suggest that the relative abilities of gammaretroviruses and lentiviruses to traverse 
the nuclear envelope dictate the differential abilities of these viruses to transduce 
nondividing cells. Models invoking a nuclear import role for Vpr/Vpx proteins have 
been supported by the fact that these proteins exhibit a nuclear localization (154). Our 
study demonstrated an alternative explanation that the differential ability of lentiviruses 
and gammaretroviruses to transduce nondividing macrophages is dictated by the degree 
to which they are sensitive to a restriction that acts prior to or at the level of reverse 
transcription. Actually, in another study by our group, it was observed that MLV 
infection of artificially growth-arrested HeLa cells was blocked at the level of 
integration and this block was mechanistically distinct from the block observed in 
natural nondividing macrophages where MLV transduction was inhibited either prior to 
or at the level of reverse transcription of viral cDNA. While our data argues against the 
possibility that nuclear access is blocked during MLV infection of nondividing 
 127
macrophages, it is possible that the restriction is located in the nucleus and that Vpx 
must localize to the nucleus in order to counteract the restriction. 
Our studies suggest that the same restriction may antagonize HIV-1 infection in 
monocytes and in macrophages. However, the degree to which HIV-1 is restricted in 
monocytes and macrophages differs considerably. In the absence of Vpx, HIV-1 still has 
the ability to transduce macrophages to some degree. Nevertheless, the efficiency with 
which HIV-1 transduces macrophages is greatly increased by Vpx. Therefore, while 
infection of macrophages by HIV-1 is antagonized by a restriction, this restriction is not 
sufficient to completely block transduction of these cells by HIV-1. In contrast, 
monocytes are totally refractory to HIV-1 infection in the absence of Vpx. Therefore, 
monocytes can be considered nonpermissive and macrophages semipermissive to HIV-1 
transduction. The extent to which monocytes and macrophages are permissive to 
infection may relate to the levels at which the restriction is expressed in these cells. A 
similar situation is seen with APOBEC3G, in that some cell lines are semipermissive 
with regards to Vif-deleted virus (30). 
Our study underscores the powerful degree to which restrictions shape lentivirus 
biology. Primate lentiviruses exhibit tropism for macrophage lineage cells, and 
reservoirs of tissue macrophages are evident in the gut, lung, lymph nodes, and CNS 
(170). Tropism is dictated primarily by the expression of specific coreceptor molecules 
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(mainly CCR5) on macrophages that permit virus binding and entry (reviewed by Gorry 
et al (171)). Our study reveals a second level of tropism that is manifest post-entry, and 
our findings would suggest that the ability of primate lentiviruses and perhaps 
nonprimate lentiviruses to establish reservoirs in myeloid lineage cells is dependent 
upon their ability to counteract a myeloid cell-specific restriction. Given the potency 
with which the restriction antagonizes primate lentivirus infection, identification of the 
restriction itself as well as pharmacologic agents that harness restrictions within 
macrophages are important objectives.  
6.2 Vpx but not Vpr Removes a Restriction in Myeloid Cells 
This study demonstrated that the restriction influencing infection of myeloid cells 
by SIV, HIV-1 or MLV is sensitive to neutralization by Vpx only, but not SIVSM Vpr or 
HIV-1 Vpr. The Vpx gene of the HIV-2 group, which includes HIV-2, SIVSM, and 
SIVMAC, arose by duplication of the Vpr gene within this group (172, 173), which 
diverged from the other primate lentiviral groups around 200 years ago (173). While 
Vpx represents a duplication event, it does not share all the functional properties of Vpr. 
Vpr induces cell cycle arrest, whereas Vpx does not (38). Conversely, the ability to 
neutralize a restriction in myeloid cells is governed by Vpx but not Vpr (Table 6-1). 
Presumably, this activity was manifest in the ancestral Vpr gene, but for unknown 
reasons  has  been lost in the HIV-1 and SIVAGM  groups. It is possible  that  loss in the  
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HIV-1 Vpr HIV-2/SIVSM Vpr HIV-2/SIVSM Vpx 
G2 cell cycle arrest G2 cell cycle arrest No 
UDG association UDG association No 
Promote macrophage 
infection possibly by 
facilitating nuclear 
import of PIC 
Not clear Not clear 
No No 
Overcome a myeloid cell 
restriction factor and 
rescue a block at reverse 
transcription 
 
Table 6-1. Functional comparison of HIV-1 Vpr, HIV-2/SIVSM Vpr and 
HIV-2/SIVSM Vpx based on this study. 
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ability to counteract the myeloid cell restriction was compensated for by acquisition of 
partial resistance to the restriction, as in the case of HIV-1. 
Another interesting observation is that the ability of SIVSM Vpx to neutralize the 
restriction factor in myeloid cells is inhibited by HIV-1 Vpr, demonstrated by the 
observation that Vpx enhances infectivity of Vpr-deleted but not wild-type HIV-1. 
Packaging of HIV-1 Vpr in a chimeric HIV-1 containing Vpx dramatically decreased its 
infection of macrophages. However, SIV Vpr does not inhibit the ability of SIVSM Vpx 
to neutralize the restriction. Therefore, one possibility is that the packaging of Vpx is 
inefficient because of competition for packaging with HIV-1 Vpr. In the case of SIV, 
both Vpx and SIV Vpr proteins are naturally packaged within virions. However, in our 
study, Vpx was packaged into wild-type and ΔVpr HIV-1 virions to similar levels. This 
argues against competition for packaging. Alternatively, HIV-1 Vpr may inhibit Vpx 
function in target cells by competing for binding to the restriction.  
Our study also reveals a paradox with regards to the functional consequences of 
HIV-1 Vpr and HIV-2/SIV Vpx interaction with DDB1. DDB1 mediates the cell cycle 
arrest property of HIV-1 Vpr. DDB1 was also necessary for the ability of SIV Vpx to 
counteract the macrophage restriction. However, SIV Vpx, although able to interact with 
DDB1, does not induce cell cycle arrest. Furthermore, the ability of HIV-1 Vpr to 
interact with DDB1 does not appear sufficient to confer upon HIV-1 Vpr the ability to 
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efficiently counteract the macrophage restriction. Therefore, there are likely to be 
different biological outcomes that are dictated by the nature of the interactions that 
HIV-1 Vpr and SIV Vpx forge with DDB1 and its associated E3 ubiquitin ligase 
complex components. Further insight into the mechanisms employed by HIV-1 Vpr and 
HIV-2/SIVSM Vpx to enhance macrophage infection may be revealed once the 
macrophage restriction itself is identified. 
6.3 Vpx Function Requires Proteasome/Ubiquitylation Pathway and DDB1 
Interaction 
Our study suggests that the function of Vpx to antagonize an antiviral restriction in 
macrophages requires functional proteasome. A role for the proteasome/ubiquitin system 
is provided by our demonstration that ubiquitylation mutants of Vpx are functionally 
attenuated and treatment of macrophages with proteasome disrupting agents specifically 
reduces the ability of Vpx to enhance permissivity of macrophages to HIV-1 or MLV 
infection. 
Our study also implicates DDB1 as a cellular cofactor of Vpx which is required for 
the ability of Vpx to counteract the macrophage restriction. DDB1 silencing in 
macrophages specifically impaired the ability of Vpx to enhance infectivity of 
macrophages by HIV-1. Further experiments are required to determine whether DDB1 
association accounts, in totality, for the biological activity of Vpx. DDB1 silencing did 
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not completely impair Vpx function to enhance HIV-1 infection in macrophages. 
However, RNA silencing failed to completely deplete DDB1 from primary macrophages, 
and therefore, residual DDB1 may allow some retention of Vpx activity. This study also 
presents evidence that DDB1 binds to ubiquitylated Vpx and that lysine mutants of Vpx 
which are inefficiently ubiquitylated exhibit reduced DDB1 binding and are impaired in 
their ability to enhance macrophage infection by HIV-1. Using a Vpx mutant lacking 
lysine residues, Vpx ubiquitylation is found to be important for association with DDB1 
and to counteract the macrophage restriction.  
Although the loss of Vpx function was attributed to lack of ubiquitylation and loss 
of DDB1 binding, there is another possibility that loss of function of the mutant protein 
was due to indirect effects of the mutations on protein structure. At the very least, the 
Vpx lysine mutant is packaged within virions, which suggests that it is competent for 
interaction with the p6 domain of the Gag polyprotein. As with DDB1 silencing, 
mutation of all four lysines in Vpx did not abrogate Vpx function completely. Therefore, 
ubiquitylation and DDB1 association may not fully account for the biological activity of 
Vpx in macrophages. However, poly ubiquitylation forms of Vpx were still evident in 
cells transfected with a Vpx mutant lacking all lysine residues. This suggests some 
degree of Vpx ubiquitylation on nonlysine residues. Identification and mutagenesis of all 
ubiquitylation residues on Vpx will be required before the degree to which Vpx activity 
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depends upon ubiquitylation can fully be assessed. Furthermore, the ubiquitylation of 
Vpx was examined in 293T cells. Due to technical obstacles in transfection of primary 
macrophages, at present it is not possible to evaluate the extent of Vpx ubiquitylation in 
primary macrophages and for this reason, it is not possible to direcely assess whether the 
Vpx biological activity was dependent on Vpx ubiquitylation. 
Our study suggests that DDB1 is not required for Vpx ubiquitylation but that Vpx 
ubiquitylation is necessary for association with DDB1. Therefore, the loss of function 
observed with the Vpx lysine mutant is likely to reflect a loss in DDB1 binding. 
Although SIV Vpr did not counteract the macrophage restriction, fusion with DDB1 
partially conferred this ability. This suggests that the function of Vpx may be to tether 
DDB1 to the reverse transcription complex upon which the restriction acts. Although 
Vpx is a virion protein, whether DDB1 itself is packaged within virions remains unclear. 
However, since silencing of DDB1 in the target cell inhibited the ability of Vpx to 
enhance macrophage infection by HIV-1, this suggests that Vpx usurps DDB1 after 
infection of the target cell and likely, within the context of the reverse transcription 
complex.  
6.4 Characteristics of the Restriction Factor in Myeloid Cells 
While the restriction that is counteracted by Vpx is as yet unidentified, it exhibits 
unique characteristics when compared other known antiviral restrictions. Viral Vif and 
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Vpu proteins that neutralize the antiviral restrictions APOBEC3G and tetherin/BST-2 
respectively, carry out their function in the virus producing cell. Although some Vif is 
packaged within virions, there is no evidence that packaged Vif has a functional role in 
viral infection. By comparison, the ability of Vpx to neutralize the myeloid cell 
restriction appears to require that Vpx is packaged within virions. Indeed, Vpx protein 
that was packaged into virions effected a durable removal of the block to subsequent 
infection by a restricted virus. This phenomenon is unprecedented in the arena of retroviral 
restrictions and suggests that the restriction has an extremely low turnover rate and takes 
a considerable time to recover after neutralization by Vpx.  
The demonstration that the biological activity of Vpx required association with 
DDB1 has parallels with viral proteins that circumvent the interferon response. For 
example, the V protein of the paramyxovirus simian virus 5, requires DDB1 to promote 
targeted degradation of STAT1 (174). However, of the various strategies used by viruses 
to impair the interferon response, all operate after initial infection and de novo 
expression of the viral defense protein. In this way, viruses prevent the infected cell 
from subsequently mounting an interferon response that would prevent surrounding cells 
from being infected by progeny virus. In the case of Vpx, the restriction must be 
neutralized by virion-associated Vpx in order for establishment of infection to occur. 
This indicates that the restriction is constitutively active in macrophages as opposed to 
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being induced upon infection. 
The expression level of the restriction factor may decide the degree to which 
lentiviruses are restricted in myeloid cells. Quiescent monocytes are nonpermissive to 
HIV-1 infection, while differentiated macrophages are semipermissive to HIV-1 
infection. This may relate to the different levels to which the restriction is expressed in 
monocytes and macrophages. Alternatively, because of low dNTP levels in monocytes, 
reverse transcription is inefficient in these cells (136). Since the restriction acts primarily 
at the reverse transcription step, the restriction may be able to more effectively perturb 
cDNA synthesis in an environment that is suboptimal for reverse transcription.  
6.5 Restrictions as Novel Targets for Antiviral Therapy 
During the long term host-virus interaction, viral hosts developed different ways to 
protect themselves from viruses. Defense against infection by viruses is primarily 
mediated through classical adaptive immune response, in which specialized B, T helper 
and cytolytic T cells recognize foreign antigens and clonally expand upon engagement 
of their antigen receptor. As a result, the invading viruses are controlled by antibodies 
that neutralize the viruses and by cytotoxic cells that recognize and kill infected cells. 
However, the research on restriction factors has revealed an additional line of host 
defense against viruses such as HIV-1. Cells employ restriction as an innate strategy to 
restrict viral invasion. Unfortunately, primate lentiviruses have evolved a strategy to 
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counteract these cellular restriction factors over the course of evolution, by expressing 
viral proteins that can oppose the antiviral action of the restriction factor. The interaction 
between viral gene products and their cellular factors is still a relatively unexplored area. 
Our study provides evidence for a novel restriction that is expressed by 
monocytes/macrophages and which potently antagonizes HIV, SIV, and MLV infection. 
Study of the restriction factor and how the viruses protect themselves from this cellular 
restriction provides deeper insights into host-virus interaction and the goal is to harness 
this cellular restriction as the basis for a novel therapeutic strategy against HIV 
infection.  
6.6 Future Directions 
The most important goal of this study is to identify the antiviral restriction factor in 
monocytes and macrophages and to understand how the block occurs. The elucidation of 
the full restriction pathway is only possible after the identification of the restriction itself. 
Identification of this restriction may uncover another target for drug development. 
The mechanism of how exactly this restriction inhibits the virion infectivity 
remains unclear. It is crucial to understand how the restriction act as a viral inhibitor, 
which component of the viruses is the target of this restriction, and whether the 
restriction blocks viral infection directly or indirectly through other proteins. 
Understanding this antiviral mechanism may uncover a novel antiviral pathway in host 
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cells and suggest new strategies for the development of antiviral therapies. 
Another goal is to determine whether Vpx interacts with the restriction directly, or 
through a complex involving some cofactors. Although our study suggested 
proteasome/ubiquitylation pathway and DDB1 interaction were required for Vpx 
function, the pathways that underlie the ability of Vpx to overcome this restriction factor 
are not well understood. 
Although our studies provide insight into mechanisms that restrict retrovirus 
infection of nondividing myeloid cells, there still remains the question as to how viral 
genomes access the nuclear compartment. Presumably, the ability to traverse the nuclear 
envelope appears to be an intrinsic property of retroviruses and lentiviruses rather than a 
characteristic that distinguishes these viruses. However, further experiments are needed 
to confirm this hypothesis. 
In our study, an interesting comparison between HIV-1 Vpr, SIV Vpx and SIV Vpr 
was revealed. While SIV Vpx originally evolved from Vpr by a duplication event, it 
does not share all the functional properties of Vpr. Answers to questions like how Vpx 
acquired the ability to overcome the cellular restriction over evolution, or if Vpr lost its 
function in inhibiting the restriction during evolution remain unclear. I also observed that 
HIV-1 Vpr inhibited the ability of Vpx to overcome the restriction, while SIV Vpr did 
not. The mechanism behind this observation is not yet understood. 
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HIV-1 did not evolve a gene with Vpx function even though the virus is partially 
restricted in macrophages. The explanation for this observation remains unclear. The 
activity to overcome the restriction may be manifested in the primary HIV-1 Vpr. 
However, in our study, primary Vpr alleles fail to overcome the restriction. Another 
possibility is that it may be beneficial to HIV-1 to be partially restricted in macrophages. 
HIV-1 infection of CD4+ T cells is cytopathic and eventually leads to death of infected 
CD4+ T cells. However, HIV-1 infection does not impact macrophage viability to the 
same extent (175). HIV-1 may become cytopathic to macrophages once a higher level of 
infection is obtained. Macrophages serve as a viral reservoir and play a role in viral 
dissemination and persistence. Therefore, it may be a selective advantage for the viruses 
to be partially suppressed in macrophages, thus the infection is less cytopathic. I did 
some preliminary experiments that showed that HIV-1 containing Vpx induced higher 
cytopathic effect on macrophages. However, further studies are required to verify this 
hypothesis. 
In addition, it remains unclear whether Vpx protein plays a role in HIV-1 infection 
of other cells such as dendritic cells, or CD4+ T cells. CD4+ T cells are the major HIV-1 
reservoir in vivo and dendritic cells are of great importance for the dissemination and 
persistence of the viruses. Understanding the function of Vpx in these cells would help 
us to gain more insights into how HIV-1 establishes a persistent infection. 
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Finally, our results indicate that both lentiviruses and other retroviruses such as 
MLV are partially or fully restricted by the same myeloid cell restriction. This suggests a 
possibly universal function of this restriction on diverse virus families. Studies on the 
sensitivity of other viruses to the restriction are therefore required. 
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